


RN 381689-04-9 CAPLUS

CN 2-Cyclopentene-1-acetic acid, 4-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-, methyl ester, (1R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log hold

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
138.42	2121.98

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-18.00	-186.75

CA SUBSCRIBER PRICE

SESSION WILL BE HELD FOR 60 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 10:52:28 ON 19 SEP 2006

L30 ANSWER 12 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:242160 CAPLUS <<LOGINID::20060919>>

DOCUMENT NUMBER: 138:271705

TITLE: Preparation of triazinyl and other carboxamides as inhibitors of histone deacetylase

INVENTOR(S): Delorme, Daniel; Woo, Soon Hyung; Vaisburg, Arkadii; Moradel, Oscar; Leit, Silvana; Raepfel, Stephane; Frechette, Sylvie; Bouchain, Giliane

PATENT ASSIGNEE(S): Methylgene, Inc.; Can.

SOURCE: PCT Int. Appl., 347 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003024448	A2	20030327	WO 2002-US29017	20020912
WO 2003024448	A3	20031113		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2465978	AA	20030327	CA 2002-2465978	20020912
EP 1429765	A2	20040623	EP 2002-763627	20020912
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK			
BR 2002012510	A	20040824	BR 2002-12510	20020912
CN 1578663	A	20050209	CN 2002-822690	20020912
JP 2005508905	T2	20050407	JP 2003-528544	20020912
JP 3795044	B2	20060712		
JP 2005255683	A2	20050922	JP 2005-80310	20050318
PRIORITY APPLN. INFO.:			US 2001-322402P	P 20010914
			US 2002-391728P	P 20020626
			JP 2003-528544	A3 20020912
			WO 2002-US29017	W 20020912

OTHER SOURCE(S): MARPAT 138:271705

GI



AB The invention relates to triazines (shown as I; variables defined below; e.g. 4-[[4-amino-6-(2-indanylamino)-[1,3,5]triazin-2-ylamino]methyl]-N-(2-aminophenyl)benzamide) and Cy<sup>3</sup>-X<sup>1</sup>-Ar<sup>2</sup>-(C(R<sup>5</sup>):C(R<sup>6</sup>))qC(O)NH-Ay<sup>2</sup> (II; variables defined below; e.g. ), many of which are N-(o-aminophenyl)carboxamides, as inhibitors of histone deacetylase (data

included for many I and II). The invention provides compds. and methods for inhibiting histone deacetylase enzymic activity. The invention also provides compns. and methods for treating cell proliferative diseases and conditions. Antineoplastic effects of some I and II are illustrated for colorectal, pulmonary and pancreatic neoplasms; also the combined antineoplastic effect of histone deacetylase inhibitors and histone deacetylase antisense oligonucleotides on tumor cells in vivo was demonstrated. For I: R3 and R4 = H, L1, Cyl and -L1-Cyl (L1 = C1-C6 alkyl, C2-C6 heteroalkyl, or C3-C6 alkenyl; Cyl = cycloalkyl, aryl, heteroaryl, or heterocyclyl) or R3 and R4 are taken together with the adjacent N atom to form a 5-, 6-, or 7-membered ring, wherein the ring atoms = C, O, S, and N, and wherein the ring is optionally substituted, and optionally forms part of a bicyclic ring system, or is optionally fused to one or two aryl or heteroaryl rings, or to one or two saturated or partially unsatd. cycloalkyl or heterocyclic rings, each of which rings and ring systems is optionally substituted. Y1 = -N(R1)(R2), -CH2-C(O)-N(R1)(R2), halogen, and H (R1 and R2 = H, L1, Cyl, and -L1-Cyl). Y2 = chemical bond or N(R0) (R0 = H, alkyl, aryl, aralkyl, and acyl); Ak1 = C1-C6 alkylene, C1-C6-heteroalkylene (preferably, in which one -CH2- is replaced with -NH-, and more preferably -NH-CH2), C2-C6 alkenylene or C2-C6 alkynylene; Ar1 = arylene or heteroarylene, either of which is optionally substituted; and Z1 = C(O)NH-Ayl and CH:CHC(O)NH-Ayl (Ayl = aryl or heteroaryl, each of which is optionally substituted). For II: Cy2 = cycloalkyl, aryl, heteroaryl, or heterocyclyl; X1 = covalent bond, M1-L2-M1, and L2-M2-L2 (L2 = chemical bond, C1-C4 alkylene, C2-C4 alkenylene, and C2-C4 alkynylene, provided that L2 is not a chemical bond when X1 is M1-L2-M1; M1 = -O-, -N(R7)-, -S-, -S(O)-, S(O)2-, -S(O)2N(R7)-, -N(R7)S(O)2-, -C(O)-, -C(O)NH-, -NHC(O)-, -NHC(O)-O- and -OC(O)NH- (R7 = H, alkyl, aryl, aralkyl, acyl, heterocyclyl, and heteroaryl); and M2 = M1, heteroarylene, and heterocyclylene, either of which rings is optionally substituted). Ar2 = arylene or heteroarylene, each of which is optionally substituted; R5 and R6 = H, alkyl, aryl, and aralkyl; q is 0 or 1; and Ay2 is a 5-6 membered cycloalkyl, heterocyclyl, or heteroaryl substituted with an amino or hydroxy moiety (preferably these groups are ortho to the amide N to which Ay2 is attached) and further optionally substituted; provided that when Cy2 is naphthyl, X1 is -CH2-, Ar2 is Ph, R5 and R6 are H, and q is 0 or 1, Ay2 is not Ph or o-hydroxyphenyl. Although the methods of preparation are not claimed, hundreds of example preps. are included.


IT 503040-12-8P, N-(2-Aminophenyl)-4-[(9-chloro-3-methyl-4-oxo-4H-isoxazolo[4,3-c]quinolin-5-yl)methyl]benzamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(drug candidate; preparation of triazinyl and other carboxamides as inhibitors of histone deacetylase for treating cell proliferative disorders)

RN 503040-12-8 CAPLUS

CN Benzamide, N-(2-aminophenyl)-4-[(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)methyl]- (9CI) (CA INDEX NAME)



IT 503040-11-7P, 4-[(9-Chloro-3-methyl-4-oxo-4H-isoxazolo[4,3-c]quinolin-5-yl)methyl]benzoic acid  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of triazinyl and other carboxamides as inhibitors of histone deacetylase for treating cell proliferative disorders)  
 RN 503040-11-7 CAPLUS  
 CN Benzoic acid, 4-[(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)methyl]- (9CI) (CA INDEX NAME)



L30 ANSWER 13 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2002:721438 CAPLUS <<LOGINID::20060919>>  
 DOCUMENT NUMBER: 138:51448  
 TITLE: Photolabeling of Human and Murine Multidrug Resistance Protein 1 with the High Affinity Inhibitor [125I]LY475776 and Azidophenacyl-[35S]Glutathione  
 AUTHOR(S): Qian, Yue-Ming; Grant, Caroline E.; Westlake, Christopher J.; Zhang, Da-Wei; Lander, Peter A.; Shepard, Robert L.; Dantzig, Anne H.; Cole, Susan P. C.; Deeley, Roger G.  
 CORPORATE SOURCE: Cancer Res. Lab., Dep Pathol., Queen's Univ., Kingston, ON, K7L 3N6, Can.  
 SOURCE: Journal of Biological Chemistry (2002), 277(38), 35225-35231  
 CODEN: JBCHA3; ISSN: 0021-9258  
 PUBLISHER: American Society for Biochemistry and Molecular Biology  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 AB Multidrug resistance protein 1 (MRP1/ABCC1) is an ATP-dependent transporter of structurally diverse organic anion conjugates. The protein also actively transports a number of non-conjugated chemotherapeutic drugs and certain anionic conjugates by a presently poorly understood GSH-dependent mechanism. LY475776 is a newly developed 125I-labeled azido tricyclic isoxazole that binds to MRP1 with high affinity and specificity in a GSH-dependent manner. The compound has also been shown to photolabel a site in the COOH-proximal region of MRP1's third membrane spanning domain (MSD). It is presently not known where GSH interacts with the protein. Here, we demonstrate that the photolabelable GSH derivative azidophenacyl-GSH can substitute functionally for GSH in supporting the photolabeling of MRP1 by LY475776 and the transport of another GSH-dependent substrate, estrone 3-sulfate. In contrast to LY475776, azidophenacyl-[35S] photolabels both halves of the protein. Photolabeling of the COOH-proximal site can be markedly stimulated by low concns. of estrone 3-sulfate, suggestive of cooperativity between the binding of these two compds. We show that photolabeling of the COOH-proximal site by LY475776 and the labeling of both NH2- and COOH- proximal sites by

azidophenacyl-GSH requires the cytoplasmic linker (CL3) region connecting the first and second MSDs of the protein, but not the first MSD itself. Although required for binding, CL3 is not photolabeled by azidophenacyl-GSH. Finally, we identify non-conserved amino acids in the third MSD that contribute to the high affinity with which LY475776 binds to MRP1.


IT 479051-99-5, LY 475776

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(photolabeling of human and murine multidrug resistance protein 1 with the high affinity inhibitor [125I]LY475776 and azidophenacyl-[35S]Glutathione)

RN 479051-99-5 CAPLUS

CN Cyclohexaneacetamide, N-(4-azido-3-iodophenyl)-3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 54 THERE ARE 54 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L30 ANSWER 14 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:645970 CAPLUS <<LOGINID::20060919>>

DOCUMENT NUMBER: 138:215238

TITLE: GSH-dependent photolabeling of multidrug resistance protein MRP1 (ABCC1) by [125I]LY475776 Evidence of a major binding site in the COOH-proximal membrane spanning domain

AUTHOR(S): Mao, Qingcheng; Qiu, Wei; Weigl, Kevin E.; Lander, Peter A.; Tabas, Linda B.; Shepard, Robert L.; Dantzig, Anne H.; Deeley, Roger G.; Cole, Susan P. C.  
CORPORATE SOURCE: Cancer Research Laboratories, Queen's University, Kingston, ON, K7L 3N6, Can.

SOURCE: Journal of Biological Chemistry (2002), 277(32), 28690-28699

CODEN: JBCHA3; ISSN: 0021-9258

PUBLISHER: American Society for Biochemistry and Molecular Biology

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Substrates transported by the 190-kDa multidrug resistance protein 1 (MRP1) (ABCC1) include endogenous organic anions such as the cysteinyl leukotriene C4. In addition, MRP1 confers resistance against various anti-cancer drugs by reducing intracellular accumulation by co-export of drug with reduced GSH. We have examined the properties of LY475776, an intrinsically photoactivable MRP1-specific tricyclic isoxazole modulator that inhibits leukotriene C4 transport by this protein in a GSH-dependent manner. We show that [125I]LY475776 photolabeling of MRP1 requires GSH but is also supported by several non-reducing GSH derivs. and peptide analogs. Limited proteolysis revealed that [125I]LY475776 labeling was

confined to the 75-kDa COOH-proximal half of MRP1. More extensive proteolysis generated two major 125I-labeled fragments of .apprx.56 and .apprx.41 kDa, and immunoblotting with regionally directed antibodies showed that these fragments correspond to amino acids .apprx.1045 - 1531 and .apprx.1150 - 1531, resp. However, an .apprx.33-kDa COOH-terminal immunoreactive fragment was not labeled, inferring that the major [125I]LY475776-labeling site resides approx. between amino acids 1150-1250. This region encompasses transmembrane (TM) segments 16 and 17 at the COOH-proximal end of the third membrane spanning domain of the protein. [125I]LY475776 labeling of mutant MRP1 mols. with substitutions of Trp1246 in TM17 were reduced >80% compared with wild-type MRP1, confirming that TM17 is important for LY475776 binding. Finally, vanadate-induced trapping of ADP inhibited [125I]LY475776 labeling, suggesting that ATP hydrolysis causes a conformational change in MRP1 that reduces the affinity of the protein for this inhibitor.


IT 500785-73-9, [125I]LY475776

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(GSH-dependent photolabeling of multidrug resistance protein MRP1 (ABCC1) by [125I]LY475776 Evidence of a major binding site in COOH-proximal membrane spanning domain)

RN 500785-73-9 CAPLUS

CN Cyclohexaneacetamide, N-[4-azido-3-(iodo-125I)phenyl]-3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 63 THERE ARE 63 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L30 ANSWER 15 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:240782 CAPLUS <<LOGINID::20060919>>

DOCUMENT NUMBER: 136:263153

TITLE: Stereoselective process for preparing isoxazolo-quinoline-substituted cyclohexyl derivatives

INVENTOR(S): Barnett, Charles Jackson; Gu, Rui Lin; Kobierski, Michael Edward

PATENT ASSIGNEE(S): Eli Lilly and Company, USA

SOURCE: PCT Int. Appl., 92 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002024705	A1	20020328	WO 2001-US26023	20010913
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI,				

FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP,  
 KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,  
 MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,  
 TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG,  
 KZ, MD, RU, TJ  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,  
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,  
 BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
 CA 2420210 AA 20020328 CA 2001-2420210 20010913  
 EP 1322652 A1 20030702 EP 2001-975165 20010913  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR  
 JP 2004509897 T2 20040402 JP 2002-529115 20010913  
 US 2004010005 A1 20040115 US 2003-362496 20030221  
 PRIORITY APPLN. INFO.: US 2000-234649P P 20000922  
 WO 2001-US26023 W 20010913  
 OTHER SOURCE(S): CASREACT 136:263153; MARPAT 136:263153  
 GI



AB A process for the preparation of I and derivs. thereof [R = alkyl, benzyl, aryl, heterocyclyl; A, B = N, O provided that when A = N, B = O and when B = N, A = O; G = carboxy, carboalkoxy]. Isophthalic acid was reduced (MeOH, 5%-Rh/Al, H<sub>2</sub> @ 50 psi), the resulting saturated diacid converted to the anhydride (CH<sub>2</sub>Cl<sub>2</sub>, DCC) and then to cis-1,3-cyclohexanedicarboxylic acid di-Et ester. The diester was converted to the (1R,3S)-monoethyl ester (phosphate buffer pH 7.2, Amano lipase AY30) and then to intermediate II via Curtius rearrangement (PhMe, PhO<sub>2</sub>PON<sub>3</sub>, MeOH, 110°C, 60 min). Deprotection of II (CH<sub>2</sub>Cl<sub>2</sub>, TMSI) followed by acylation with 3-(6-fluoro-2-chlorophenyl)-5-methylisoxazole-4-carbonyl chloride yielded an intermediate which upon treatment with KHMDS in DMF allowed cyclization to I [A = O; B = N; G = EtO<sub>2</sub>C]. Chemical transformations of I were also exemplified (A, B as mentioned above; G = carboxy to hydroxymethyl, aminomethyl, azidomethyl, etc.). I are inhibitors of multidrug resistance protein (MRP1) and are useful as chemotherapeutic agents (no data).


IT 347186-86-1P 347186-87-2P 347186-88-3P  
 347187-06-8P 347187-07-9P 347187-08-0P  
 347187-09-1P

RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (intermediate; stereoselective process for preparing isoxazolo-quinoline-substituted cyclohexyl derivs.)

RN 347186-86-1 CAPLUS

CN Cyclohexanecarboxylic acid, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-, ethyl ester, (1R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 347186-87-2 CAPLUS

CN Cyclohexanecarboxylic acid, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-, (1R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 347186-88-3 CAPLUS

CN Carbamic acid, [(1R,3S)-3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)cyclohexyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 347187-06-8 CAPLUS

CN Isoxazolo[4,3-c]quinolin-4(5H)-one, 9-chloro-5-[(1S,3R)-3-(hydroxymethyl)cyclohexyl]-3-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 347187-07-9 CAPLUS

CN Isoxazolo[4,3-c]quinolin-4(5H)-one, 9-chloro-3-methyl-5-[(1S,3R)-3-  
[[methylsulfonyl]oxy]methyl]cyclohexyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 347187-08-0 CAPLUS

CN Isoxazolo[4,3-c]quinolin-4(5H)-one, 5-[(1S,3R)-3-(azidomethyl)cyclohexyl]-  
9-chloro-3-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 347187-09-1 CAPLUS

CN Isoxazolo[4,3-c]quinolin-4(5H)-one, 5-[(1S,3R)-3-(aminomethyl)cyclohexyl]-  
9-chloro-3-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 347177-49-5P 347178-08-9P 347181-06-0P  
405303-10-8P


RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP  
(Preparation)

(stereoselective process for preparing isoxazolo-quinoline-substituted  
cyclohexyl derivs.)

RN 347177-49-5 CAPLUS

CN 3-Pyridinecarboxamide, N-[[ (1R,3S)-3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)cyclohexyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 347178-08-9 CAPLUS

CN Benzamide, N-[[ (1R,3S)-3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)cyclohexyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 347181-06-0 CAPLUS

CN 3-Pyridinecarboxamide, 6-chloro-N-[[ (1R,3S)-3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)cyclohexyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 405303-10-8 CAPLUS

CN 4-Pyridinecarboxamide, N-[[[(1R,3S)-3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)cyclohexyl)methyl]-2-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L30 ANSWER 16 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:175763 CAPLUS <<LOGINID::20060919>>

DOCUMENT NUMBER: 137:304252

TITLE: Tricyclic isoxazoles are novel inhibitors of the multidrug resistance protein (MRP1)

AUTHOR(S): Norman, Bryan H.; Gruber, Joseph M.; Hollinshead, Sean P.; Wilson, Joseph W.; Starling, James J.; Law, Kevin L.; Self, Tracy D.; Tabas, Linda B.; Williams, Daniel C.; Paul, Donald C.; Wagner, Margaret M.; Dantzig, Anne H.

CORPORATE SOURCE: Eli Lilly and Company, Lilly Corporate Center, Discovery Chemistry Research, Indianapolis, IN, 46285, USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (2002), 12(6), 883-886

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 137:304252

AB Tricyclic isoxazoles were identified from a screen as a novel class of selective multidrug resistance protein (MRP1) inhibitors. From a screen lead, SAR efforts resulted in the preparation of LY 402913, which inhibits MRP1

and reverses drug resistance to MRP1 substrates, such as doxorubicin, in HeLa-T5 cells ( $EC_{50}=0.90\text{ }\mu\text{M}$ ), while showing no inherent cytotoxicity. Addnl., LY 402913 inhibits ATP-dependent, MRP1-mediated LTC4 uptake into membrane vesicles prepared from the MRP1-overexpressing HeLa-T5 cells ( $EC_{50}=1.8\text{ }\mu\text{M}$ ). LY 402913 also shows selectivity (.apprx.22-fold) against the related transporter, P-glycoprotein, in HL60/Adr and HL60/Vinc cells. Finally, when dosed in combination with the oncolytic MRP1 substrate vincristine, LY 402913 delays the growth of MRP1-overexpressing tumors in vivo.


IT 246238-46-0P 246238-55-1P 246238-56-2P  
 246238-59-5P 246238-60-8P 246238-62-0P  
 246238-64-2P 246238-66-4P 246238-68-6P  
 246239-19-0P 246239-34-9P 246239-38-3P  
 246239-66-7P 246239-68-9P 472996-58-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(tricyclic isoxazoles are novel inhibitors of multidrug resistance protein (MRP1))


RN 246238-46-0 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-phenyl- (9CI) (CA INDEX NAME)




RN 246238-55-1 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 246238-56-2 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 246238-59-5 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(3,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 246238-60-8 CAPLUS

CN Benzeneacetamide, N-1,3-benzodioxol-5-yl-3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)- (9CI) (CA INDEX NAME)




RN 246238-62-0 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 246238-64-2 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 246238-66-4 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 246238-68-6 CAPLUS

CN Benzoic acid, 4-[[[3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)phenyl]acetyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 246239-19-0 CAPLUS

CN Benzeneacetamide, N-[4-(aminosulfonyl)phenyl]-3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)- (9CI) (CA INDEX NAME)




RN 246239-34-9 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 246239-38-3 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(4-hydroxy-3,5-dimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 246239-66-7 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-[4-(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 246239-68-9 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(4-cyanophenyl)- (9CI) (CA INDEX NAME)



RN 472996-58-0 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(3,5-dimethoxyphenyl)- (9CI) (CA INDEX NAME)




IT 246238-22-2 246239-75-8 472996-37-5  
472996-40-0

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)  
(tricyclic isoxazoles are novel inhibitors of multidrug resistance  
protein (MRP1))


RN 246238-22-2 CAPLUS

CN Benzamide, N-[[3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-  
yl)phenyl]methyl]-3,4,5-trimethoxy- (9CI) (CA INDEX NAME)




RN 246239-75-8 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-  
yl)-N-methyl-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 472996-37-5 CAPLUS

CN Isoxazolo[4,3-c]quinolin-4(5H)-one, 9-chloro-3-methyl-5-[3-[2-(3,4,5-  
trimethoxyphenoxy)ethyl]phenyl]- (9CI) (CA INDEX NAME)



RN 472996-40-0 CAPLUS

CN Isoxazolo[4,3-c]quinolin-4(5H)-one, 9-chloro-3-methyl-5-[3-[[[(3,4,5-trimethoxyphenyl)methyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)




IT 246238-13-1P 246238-45-9P 246240-20-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(tricyclic isoxazoles are novel inhibitors of multidrug resistance protein (MRP1))


RN 246238-13-1 CAPLUS

CN 3-Isloxazolo[4,3-c]quinolin-4(5H)-one, 9-chloro-3-methyl-5-[3-(2,4,6-trimethoxybenzyl)amino]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 246238-45-9 CAPLUS

CN Benzeneacetic acid, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)- (9CI) (CA INDEX NAME)



RN 246240-20-0 CAPLUS

CN Benzeneacetyl chloride, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)- (9CI) (CA INDEX NAME)



IT 246153-40-2P 246238-14-2P 246238-15-3P


RL: SPN (Synthetic preparation); PREP (Preparation)

(tricyclic isoxazoles are novel inhibitors of multidrug resistance protein (MRP1))

RN 246153-40-2 CAPLUS


CN 3-Isioxazolecarboxamide, N-[(1R,2R)-6-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]-5-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 246238-14-2 CAPLUS

CN 3-Isioxazolecarboxamide, N-[[2-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)phenyl]methyl]-5-methyl- (9CI) (CA INDEX NAME)



RN 246238-15-3 CAPLUS

CN 3-Isioxazolecarboxamide, N-[[4-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)phenyl]methyl]-5-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L30 ANSWER 17 OF 36 CAPLUS COPYRIGHT 2006 ACS on STM

ACCESSION NUMBER: 2001:923806 CAPLUS <<LOGINID::20060919>>

DOCUMENT NUMBER: 136:53742

TITLE: Preparation of 5H-isoxazolo[4,3-c]quinolin-4-ones as MRPl inhibitors

INVENTOR(S): Lander, Peter Ambrose; Wang, Qiuping; Vepachedu, Sreenivasarao

PATENT ASSIGNEE(S): Eli Lilly and Company, USA

SOURCE: PCT Int. Appl., 54 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001096346	A1	20011220	WO 2001-US16475	20010531
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,				

DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,  
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2411813	AA	20011220	CA 2001-2411813	20010531
AU 2001074891	A5	20011224	AU 2001-74891	20010531
EP 1301518	A1	20030416	EP 2001-941546	20010531


R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

US 2003216425	A1	20031120	US 2003-296481	20030416
US 6673809	B2	20040106		

PRIORITY APPLN. INFO.: US 2000-211430P P 20000614  
 WO 2001-US16475 W 20010531

OTHER SOURCE(S): MARPAT 136:53742

GI



AB The title compds. [I; A = II-IV; Y = ECOR1; ENR2R3; E = a bond, CH2; R1 = H, alkyl, cycloalkyl, etc.; R2 = H, alkyl, alkylaryl, aryl; R3 = H, alkyl, alkoxy, etc.], useful for inhibiting resistant neoplasms where the resistance is conferred in part or in total by MRP1 (no data), were prepared. Thus, reacting 5-(4-aminocyclopent-2-enyl)-9-chloro-3-methyl-5H-isoxazolo[4,3-c]quinolin-4-one (preparation given) with benzoyl chloride in the presence of Et3N in CH2Cl2 afforded 55% V.


IT 381688-80-8P 381688-81-9P 381688-82-0P  
 381688-83-1P 381688-84-2P 381688-85-3P  
 381688-86-4P 381688-87-5P 381688-88-6P  
 381688-89-7P 381688-90-0P 381688-92-2P  
 381688-94-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 5H-isoxazolo[4,3-c]quinolin-4-ones as MRP1 inhibitors)


RN 381688-80-8 CAPLUS

CN Benzamide, N-[4-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-2-cyclopenten-1-yl]- (9CI) (CA INDEX NAME)




RN 381688-81-9 CAPLUS

CN Urea, N-[4-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-2-cyclopenten-1-yl]-N'-phenyl- (9CI) (CA INDEX NAME)




RN 381688-82-0 CAPLUS

CN Benzeneacetamide, N-[4-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-2-cyclopenten-1-yl]-3,4,5-trimethoxy-α-oxo- (9CI) (CA INDEX NAME)




RN 381688-83-1 CAPLUS

CN Urea, N-[4-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-2-cyclopenten-1-yl]-N'-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 381688-84-2 CAPLUS

CN Benzeneacetamide, N-[4-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-2-cyclopenten-1-yl]- (9CI) (CA INDEX NAME)




RN 381688-85-3 CAPLUS

CN Benzeneacetamide, N-[4-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-2-cyclopenten-1-yl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 381688-86-4 CAPLUS

CN Benzeneacetamide, N-[4-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-2-cyclopenten-1-yl]-3,4,5-trimethoxy- (9CI) (CA INDEX NAME)



RN 381688-87-5 CAPLUS


CN Benzeneacetamide, N-[4-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-2-cyclopenten-1-yl]-3-fluoro- (9CI) (CA INDEX NAME)



RN 381688-88-6 CAPLUS

CN Carbamic acid, [(1R)-2-[[4-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-2-cyclopenten-1-yl]amino]-2-oxo-1-phenylethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 381688-89-7 CAPLUS


CN Carbamic acid, [(1S)-2-[[4-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-2-cyclopenten-1-yl]amino]-2-oxo-1-phenylethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 381688-90-0 CAPLUS

CN Benzeneacetamide, N-[4-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-2,3-dihydroxycyclopentyl]-3,4,5-trimethoxy- (9CI) (CA INDEX NAME)



RN 381688-92-2 CAPLUS


CN Benzeneacetamide, N-[4-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-2,3-dihydroxycyclopentyl]-3-fluoro- (9CI) (CA INDEX NAME)




RN 381688-94-4 CAPLUS

CN 2-Cyclopentene-1-acetamide, 4-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(3,4,5-trimethoxyphenyl)-, (1R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 381688-97-7P 381688-98-8P 381688-99-9P  
 381689-00-5P 381689-01-6P 381689-03-8P  
 381689-04-9P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation of 5H-isoxazolo[4,3-c]quinolin-4-ones as MRP1 inhibitors)  
 RN 381688-97-7 CAPLUS  
 CN Isoxazolo[4,3-c]quinolin-4(5H)-one, 9-chloro-5-[4-[(1,1-  
 dimethylethyl)dimethylsilyl]oxy]-2-cyclopenten-1-yl]-3-methyl- (9CI) (CA  
 INDEX NAME)




RN 381688-98-8 CAPLUS  
 CN Isoxazolo[4,3-c]quinolin-4(5H)-one, 9-chloro-5-(4-hydroxy-2-cyclopenten-1-  
 yl)-3-methyl- (9CI) (CA INDEX NAME)




RN 381688-99-9 CAPLUS

CN Carbonic acid, 4-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-2-cyclopenten-1-yl ethyl ester (9CI) (CA INDEX NAME)



RN 381689-00-5 CAPLUS


CN Isoxazolo[4,3-c]quinolin-4(5H)-one, 5-(4-amino-2-cyclopenten-1-yl)-9-chloro-3-methyl- (9CI) (CA INDEX NAME)



RN 381689-01-6 CAPLUS

CN Isoxazolo[4,3-c]quinolin-4(5H)-one, 5-[(1R,4S)-4-(acetyloxy)-2-cyclopenten-1-yl]-9-chloro-3-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 381689-03-8 CAPLUS

CN Propanedioic acid, [(1S,4R)-4-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-2-cyclopenten-1-yl]-, dimethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L30 ANSWER 18 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:472724 CAPLUS <<LOGINID::20060919>>  
DOCUMENT NUMBER: 135:76865  
TITLE: Preparation of N-(isoxazoloquinolinylcyclohexyl)carbox  
amides and analogs as MRP1 inhibitors  
INVENTOR(S): Bonjouklian, Rosanne; Cohen, Jeffrey Daniel; Gruber,  
Joseph Michael; Johnson, Douglas Webb; Jungheim, Louis  
Nickolaus; Kroin, Julian Stanley; Lander, Peter  
Ambrose; Lin, Ho-shen; Lohman, Mark Christopher;  
Muehl, Brian Stephen; Norman, Bryan Hurst; Patel,  
Vinod Francis; Richett, Michael Enrico; Thrasher,  
Kenneth Jeff; Vepachedu, Sreenivasarao; White, Wesley  
Todd; Xie, Yongping; York, Jeremy Schulenburg;  
Parkhurst, Brandon Lee  
PATENT ASSIGNEE(S): Eli Lilly and Co., USA; Wang, Qiuping; et al.  
SOURCE: PCT Int. Appl., 381 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001046199	A1	20010628	WO 2000-US32443	20001211
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2395513	AA	20010628	CA 2000-2395513	20001211
EP 1250340	A1	20021023	EP 2000-986242	20001211
EP 1250340	B1	20041117		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2003518125	T2	20030603	JP 2001-547109	20001211
AT 282623	E	20041215	AT 2000-986242	20001211
PT 1250340	T	20050429	PT 2000-986242	20001211
ES 2233487	T3	20050616	ES 2000-986242	20001211
US 2003100576	A1	20030529	US 2002-130800	20020521
US 6743794	B2	20040601		
US 2004176405	A1	20040909	US 2004-797362	20040310
PRIORITY APPLN. INFO.:			US 1999-171373P	P 19991222
			US 2000-226076P	P 20000817
			US 2000-234539P	P 20000922
			WO 2000-US32443	W 20001211
			US 2002-130800	A3 20020521
OTHER SOURCE(S):	MARPAT 135:76865			
REFERENCE COUNT:	4	THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT		

L30 ANSWER 19 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2001:283958 CAPLUS <<LOGINID::20060919>>  
 DOCUMENT NUMBER: 134:311201  
 TITLE: Preparation of isoxazoloquinolinones as inhibitors of  
 multidrug resistance protein 1.  
 INVENTOR(S): Bonjouklian, Rosanne; Johnson, Douglas Webb; Lander,  
 Peter Ambrose; Lohman, Mark Christopher; Patel, Vinod  
 Francis; Vepachedu, Sreenivasarao; Xie, Yongping  
 PATENT ASSIGNEE(S): Eli Lilly and Company, USA  
 SOURCE: PCT Int. Appl., 160 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001027116	A2	20010419	WO 2000-US21980	20000922
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1224189	A2	20020724	EP 2000-968314	20000922
EP 1224189	B1	20060125		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
AT 316531	E	20060215	AT 2000-968314	20000922
US 6670373	B1	20031230	US 2002-88721	20020702
US 2004077675	A1	20040422	US 2003-678891	20031003
PRIORITY APPLN. INFO.:			US 1999-158175P	P 19991007
			US 1999-169784P	P 19991209
			WO 2000-US21980	W 20000922
			US 2002-88721	A3 20020702
OTHER SOURCE(S):		MARPAT 134:311201		
GI				



AB Title compds. [I; A = atoms to form a 5-membered (substituted) heteroaryl ring containing N and a 2nd heteroatom selected from N, O, S; R = (CH<sub>2</sub>)<sub>m</sub>CHR<sub>1</sub>NHR<sub>2</sub>, OCH<sub>2</sub>CH<sub>2</sub>NHR<sub>2</sub>, NHR<sub>2</sub>, etc.; R<sub>0</sub> = H, OH, alkyl, phenylalkyl, cycloalkylalkyl; m = 0-2; R<sub>1</sub> = H, alkyl; R<sub>2</sub> = H, COR<sub>6</sub>, SO<sub>2</sub>R<sub>7</sub>, etc.; R<sub>6</sub> = alkyl, substituted cycloalkyl, aryl, OCMe<sub>3</sub>, heterocyclyl, heterocyclylalkyl, etc.; R<sub>7</sub> = alkyl, (substituted) Ph; R<sub>9</sub>-R<sub>11</sub> = H, halo, CO<sub>2</sub>R<sub>1</sub>, (substituted) aryl, thienyl, alkoxy, alkylphenyl, alkenyl], were prepared Thus, N-(3,4,5-trimethoxyphenyl)-3-[3-(2-chloro-5-fluorophenyl)-5-chloroisoxazol-4-oyl]aminophenylacetamide (preparation given) was stirred with K<sub>2</sub>CO<sub>3</sub> at -10° for 3 h to give 31.1% title compound (II). I were said to demonstrate a significant effect in reversing MRP1 multiple drug resistance. I drug formulations are given.


IT 334970-75-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of isoxazoloquinolinones as inhibitors of multidrug resistance protein 1)

RN 334970-75-1 CAPLUS

CN Benzeneacetamide, 3-[9-chloro-3-(hydroxymethyl)-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl]-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




IT 334970-55-7P 334970-58-0P 334970-59-1P  
 334970-60-4P 334970-61-5P 334970-62-6P  
 334970-63-7P 334970-64-8P 334970-66-0P  
 334970-67-1P 334970-68-2P 334970-69-3P  
 334970-70-6P 334970-71-7P 334970-72-8P  
 334970-73-9P 334970-74-0P 334970-76-2P  
 334970-77-3P 334970-78-4P 334970-79-5P  
 334970-80-8P 334970-81-9P 334970-82-0P  
 334970-83-1P 334970-84-2P 334970-85-3P  
 334970-86-4P 334970-87-5P 334970-88-6P  
 334970-89-7P 334970-90-0P 334970-91-1P  
 334970-92-2P 334970-93-3P 334970-94-4P  
 334970-95-5P 334970-96-6P 334970-97-7P  
 334970-98-8P 334970-99-9P 334971-00-5P  
 334971-01-6P 334971-02-7P 334971-03-8P  
 334971-04-9P 334971-05-0P 334971-06-1P  
 334971-07-2P 334971-08-3P 334971-09-4P  
 334971-10-7P 334971-11-8P 334971-12-9P  
 334971-13-0P 334971-14-1P 334971-15-2P  
 334971-16-3P 334971-17-4P 334971-18-5P  
 334971-19-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of isoxazoloquinolinones as inhibitors of multidrug resistance protein 1)


RN 334970-55-7 CAPLUS

CN Benzeneacetamide, 3-(3,9-dichloro-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 334970-58-0 CAPLUS

CN Benzeneacetamide, 3-[9-chloro-3-(4-morpholinyl)-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl]-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 334970-59-1 CAPLUS

CN Benzeneacetamide, 3-[9-chloro-2-(1,1-dimethylethyl)-2,4-dihydro-4-oxo-5H-pyrazolo[4,3-c]quinolin-5-yl]-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 334970-60-4 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-2,4-dihydro-4-oxo-5H-pyrazolo[4,3-c]quinolin-5-yl)-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 334970-61-5 CAPLUS

CN Benzeneacetamide, 3-[9-chloro-2-(1,1-dimethylethyl)-2,4-dihydro-4-oxo-5H-pyrazolo[4,3-c]quinolin-5-yl]-N-methyl-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 334970-62-6 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-2,4-dihydro-4-oxo-5H-pyrazolo[4,3-c]quinolin-5-yl)-N-methyl-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 334970-63-7 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-2,4-dihydro-2-methyl-4-oxo-5H-pyrazolo[4,3-c]quinolin-5-yl)-N-methyl-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 334970-64-8 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-2,4-dihydro-2-methyl-4-oxo-5H-pyrazolo[4,3-c]quinolin-5-yl)-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 334970-66-0 CAPLUS

CN Benzeneacetamide, 3-(3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 334970-67-1 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-4-oxo-3-phenylisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 334970-68-2 CAPLUS

CN Benzeneacetamide, 3-(9-fluoro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 334970-69-3 CAPLUS

CN Benzeneacetamide, 3-(9-methoxy-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 334970-70-6 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-hexyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 334970-71-7 CAPLUS

CN Benzeneacetamide, 3-(7-fluoro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 334970-72-8 CAPLUS

CN Benzeneacetamide, 3-(7-methoxy-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 334970-73-9 CAPLUS

CN Benzeneacetamide, 3-(7-bromo-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 334970-74-0 CAPLUS

CN Benzeneacetamide, 3-[9-chloro-4-oxo-3-[(tetrahydro-2H-pyran-2-yl)oxy]methyl]isoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 334970-76-2 CAPLUS

CN Benzeneacetamide, 3-[3-(azidomethyl)-9-chloro-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl]-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 334970-77-3 CAPLUS

CN Carbamic acid, [[9-chloro-4,5-dihydro-4-oxo-5-[3-[2-oxo-2-[(3,4,5-trimethoxyphenyl)amino]ethyl]phenyl]isoxazolo[4,3-c]quinolin-3-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 334970-78-4 CAPLUS

CN Benzeneacetamide, 3-[3-(aminomethyl)-9-chloro-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl]-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 334970-79-5 CAPLUS

CN Benzeneacetamide, 3-[9-chloro-3-[(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)methyl]-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl]-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 334970-80-8 CAPLUS

CN Benzeneacetamide, 3-[9-chloro-3-[(methylthio)methyl]-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl]-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 334970-81-9 CAPLUS

CN Benzeneacetamide, 3-[9-chloro-4-oxo-3-(3-thiazolidinylmethyl)isoxazolo[4,3-c]quinolin-5(4H)-yl]-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 334970-82-0 CAPLUS

CN Benzeneacetamide, 3-(9-iodo-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 334970-83-1 CAPLUS

CN Benzeneacetamide, 3-[3-methyl-4-oxo-9-(2-thienyl)isoxazolo[4,3-c]quinolin-5(4H)-yl]-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 334970-84-2 CAPLUS

CN Benzeneacetamide, 3-[3-methyl-9-(1-naphthalenyl)-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl]-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 334970-85-3 CAPLUS

CN Benzeneacetamide, 3-[9-(4-methoxyphenyl)-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl]-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 334970-86-4 CAPLUS

CN Benzeneacetamide, 3-[9-(4-chlorophenyl)-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl]-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 334970-87-5 CAPLUS

CN Benzeneacetamide, 3-(9-ethenyl-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 334970-88-6 CAPLUS

CN Benzeneacetamide, 3-[3-methyl-4-oxo-9-(phenylmethyl)isoxazolo[4,3-c]quinolin-5(4H)-yl]-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 334970-89-7 CAPLUS

CN Isoxazolo[4,3-c]quinoline-9-carboxylic acid, 4,5-dihydro-3-methyl-4-oxo-5-[3-[2-oxo-2-[(3,4,5-trimethoxyphenyl)amino]ethyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 334970-90-0 CAPLUS

CN Isoxazolo[4,3-c]quinoline-9-carboxylic acid, 4,5-dihydro-3-methyl-4-oxo-5-[3-[2-oxo-2-[(3,4,5-trimethoxyphenyl)amino]ethyl]phenyl]- (9CI) (CA INDEX NAME)




RN 334970-91-1 CAPLUS

CN Benzeneacetamide, 3-(8-iodo-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 334970-92-2 CAPLUS

CN Benzeneacetamide, 3-[3-methyl-4-oxo-8-[4-(trifluoromethyl)phenyl]isoxazolo[4,3-c]quinolin-5(4H)-yl]-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 334970-93-3 CAPLUS

CN Benzeneacetamide, 3-[3-methyl-8-(1-naphthalenyl)-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl]-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 334970-94-4 CAPLUS

CN Benzeneacetamide, 3-[3-methyl-4-oxo-8-(2-thienyl)isoxazolo[4,3-c]quinolin-5(4H)-yl]-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 334970-95-5 CAPLUS

CN Benzeneacetamide, 3-[8-(4-methoxyphenyl)-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl]-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 334970-96-6 CAPLUS

CN Benzeneacetamide, 3-[8-(4-chlorophenyl)-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl]-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 334970-97-7 CAPLUS

CN Isoxazolo[4,3-c]quinoline-8-carboxylic acid, 4,5-dihydro-3-methyl-4-oxo-5-[3-[2-oxo-2-[(3,4,5-trimethoxyphenyl)amino]ethyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 334970-98-8 CAPLUS

CN Isoxazolo[4,3-c]quinoline-8-carboxylic acid, 4,5-dihydro-3-methyl-4-oxo-5-[3-[2-oxo-2-[(3,4,5-trimethoxyphenyl)amino]ethyl]phenyl]- (9CI) (CA INDEX NAME)




RN 334970-99-9 CAPLUS

CN Benzeneacetamide, 3-[9-chloro-3-(methylthio)-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl]-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 334971-00-5 CAPLUS

CN Benzeneacetamide, 3-[9-chloro-3-(diethylamino)-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl]-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 334971-01-6 CAPLUS

CN Benzeneacetamide, 3-[9-chloro-3-(dipropylamino)-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl]-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 334971-02-7 CAPLUS

CN Benzeneacetamide, 3-[9-chloro-3-[(4-methoxyphenyl)amino]-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl]-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 334971-03-8 CAPLUS

CN Benzeneacetamide, 3-[9-chloro-4-oxo-3-(3-thiazolidinyl)isoxazolo[4,3-c]quinolin-5(4H)-yl]-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 334971-04-9 CAPLUS

CN Benzeneacetamide, 3-[9-chloro-4-oxo-3-[(phenylmethyl)thio]isoxazolo[4,3-c]quinolin-5(4H)-yl]-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 334971-05-0 CAPLUS

CN Benzeneacetamide, 3-[9-chloro-3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl]-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 334971-06-1 CAPLUS

CN Benzeneacetamide, 3-[9-chloro-4-oxo-3-(2-pyridinylthio)isoxazolo[4,3-c]quinolin-5(4H)-yl]-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 334971-07-2 CAPLUS

CN Benzeneacetamide, 3-[9-chloro-4-oxo-3-(phenylthio)isoxazolo[4,3-c]quinolin-5(4H)-yl]-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 334971-08-3 CAPLUS

CN Serine, N-[9-chloro-4,5-dihydro-4-oxo-5-[3-[2-oxo-2-[(3,4,5-trimethoxyphenyl)amino]ethyl]phenyl]isoxazolo[4,3-c]quinolin-3-yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 334971-09-4 CAPLUS

CN Benzeneacetamide, 3-[9-chloro-3-[(4-fluorophenyl)amino]-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl]-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 334971-10-7 CAPLUS

CN Benzeneacetamide, 3-[9-chloro-4-oxo-3-(phenylamino)isoxazolo[4,3-c]quinolin-5(4H)-yl]-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 334971-11-8 CAPLUS

CN Benzeneacetamide, 3-[9-chloro-3-[(2-methoxyethyl)amino]-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl]-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)



RN 334971-12-9 CAPLUS


CN Valine, N-[9-chloro-4,5-dihydro-4-oxo-5-[3-[2-oxo-2-[(3,4,5-trimethoxyphenyl)amino]ethyl]phenyl]isoxazolo[4,3-c]quinolin-3-yl]-, methyl ester (9CI) (CA INDEX NAME)



RN 334971-13-0 CAPLUS

CN L-Proline, 1-[9-chloro-4,5-dihydro-4-oxo-5-[3-[2-oxo-2-[(3,4,5-trimethoxyphenyl)amino]ethyl]phenyl]isoxazolo[4,3-c]quinolin-3-yl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 334971-14-1 CAPLUS


CN Phenylalanine, N-[9-chloro-4,5-dihydro-4-oxo-5-[3-[2-oxo-2-[(3,4,5-trimethoxyphenyl)amino]ethyl]phenyl]isoxazolo[4,3-c]quinolin-3-yl]-,

methyl ester (9CI) (CA INDEX NAME)




RN 334971-15-2 CAPLUS

CN Alanine, N-[9-chloro-4,5-dihydro-4-oxo-5-[3-[2-oxo-2-[(3,4,5-trimethoxyphenyl)amino]ethyl]phenyl]isoxazolo[4,3-c]quinolin-3-yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 334971-16-3 CAPLUS

CN Glycine, N-[9-chloro-4,5-dihydro-4-oxo-5-[3-[2-oxo-2-[(3,4,5-trimethoxyphenyl)amino]ethyl]phenyl]isoxazolo[4,3-c]quinolin-3-yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 334971-17-4 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-ethoxy-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 334971-18-5 CAPLUS

CN Benzeneacetamide, 3-[9-chloro-3-(1-methylethoxy)-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl]-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)



RN 334971-19-6 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methoxy-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




IT 334971-60-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of isoxazoloquinolinones as inhibitors of multidrug resistance protein 1)

RN 334971-60-7 CAPLUS

CN Benzeneacetamide, 3-[9-chloro-3-[[[(methylsulfonyl)oxy]methyl]-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl]-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)



L30 ANSWER 20 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:88193 CAPLUS <<LOGINID::20060919>>

DOCUMENT NUMBER: 134:311147

TITLE: Organic azides in heterocyclic synthesis. 27.  
Heteroelectrocyclic reaction of 4-azido-3-hydrazonoalkyl-quinolines to 2-arylamino-pyrazolo[4,3-c]quinolones

AUTHOR(S): Hojas, Gerhard; Fiala, Werner; Stadlbauer, Wolfgang  
CORPORATE SOURCE: Department of Chemistry, Organic Synthesis Group,  
Karl-Franzens-University of Graz, Graz, A-8010,  
Austria

SOURCE: Journal of Heterocyclic Chemistry (2000), 37(6),  
1559-1569

CODEN: JHTCAD; ISSN: 0022-152X

PUBLISHER: HeteroCorporation

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 134:311147

AB 4-Azido-3-acylquinolones obtained from 4-hydroxy deriys. via tosylates or chlorides, reacted with arylhydrazines to generate 4-azido-3-hydrazonoalkylquinolines. Thermolysis of 4-azido-3-hydrazonoalkylquinolines gave ring closure products which were assigned to 2-arylamino-pyrazolo[4,3-c]quinolones. The thermal decomposition conditions of the azides 4-azido-3-acylquinolones and 4-azido-3-hydrazonoalkylquinolines were studied by differential scanning calorimetry (DSC).

IT 335151-93-4P 335151-96-7P 335152-00-6P


335152-03-9P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation and thermal decomposition of


[(arylhydrazono)alkyl] (azido)quinolinon  
es to (arylamino)pyrazolo[4,3-c]quinolinones)

RN 335151-93-4 CAPLUS


CN 4H-Pyrazolo[4,3-c]quinolin-4-one, 2,5-dihydro-3-methyl-5-phenyl-2-(phenylamino)- (9CI) (CA INDEX NAME)




RN 335151-96-7 CAPLUS  
CN 4H-Pyrazolo[4,3-c]quinolin-4-one, 2,5-dihydro-3-methyl-2-[(4-nitrophenyl)amino]-5-phenyl- (9CI) (CA INDEX NAME)



RN 335152-00-6 CAPLUS  
CN 4H-Pyrazolo[4,3-c]quinolin-4-one, 2-[(3-chlorophenyl)amino]-2,5-dihydro-3-methyl-5-phenyl- (9CI) (CA INDEX NAME)



RN 335152-03-9 CAPLUS  
CN 4H-Pyrazolo[4,3-c]quinolin-4-one, 2,5-dihydro-5-phenyl-2-(phenylamino)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L30 ANSWER 21 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2000:707169 CAPLUS <<LOGINID::20060919>>  
DOCUMENT NUMBER: 133:290336  
TITLE: Coordination compounds with ligands of a nitrogen heterocycle and organic electroluminescent device using these complexes  
INVENTOR(S): Kim, Kong-Kyeom; Son, Se-Hwan; Kim, Ok-Hee; Yoon, Seok-Hee; Bae, Jae-Soon; Lee, Youn-Gu; Kim, Hyo-Seok  
PATENT ASSIGNEE(S): LG Chemical, Ltd., S. Korea

SOURCE: PCT Int. Appl., 47 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000058315	A1	20001005	WO 2000-KR289	20000330
W: CA, CN, JP				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
KR 2000061807	A	20001025	KR 1999-11160	19990331
CA 2333731	AA	20001005	CA 2000-2333731	20000330
EP 1084127	A1	20010321	EP 2000-913155	20000330
EP 1084127	B1	20030604		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002540210	T2	20021126	JP 2000-608016	20000330
US 6383666	B1	20020507	US 2000-540837	20000331
PRIORITY APPLN. INFO.:			KR 1999-11160	A 19990331
			WO 2000-KR289	W 20000330


OTHER SOURCE(S): MARPAT 133:290336

AB Disclosed are new coordination compds. having light-emitting and electron-transporting characteristics, such as ZnL2 (HL = 3-(2-benzothiazolyl)-4-hydroxy-2H-1-benzopyran-2-one). Also disclosed are organic EL (electroluminescent) devices using these coordination compds. as electron-transporting materials. The coordination compds. were used to form a light-emitting layer with or without doping of another light-emitting material. The coordination compds. can also be used in an electron-transporting layer of the organic EL device. The organic EL devices incorporating the coordination compds. have high thermal stability. Thus ZnL2 was prepared by 1st reacting 4-hydroxycoumarin with Ph isothiocyanate, followed by ring closure and reaction with Zn(OAc)2.

IT 299158-89-7P  
 RL: DEV (Device component use); SPN (Synthetic preparation); PREP (Preparation); USES (Uses)  
 (preparation as electron-transporting material for electroluminescent devices)

RN 299158-89-7 CAPLUS

CN Zinc, bis[3-(2-benzothiazolyl-κN3)-1-phenyl-2,4(1H,3H)-quinolinedionato-κO4]-, (T-4)- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L30 ANSWER 22 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 1999:659241 CAPLUS <<LOGINID::20060919>>  
 DOCUMENT NUMBER: 131:286506  
 TITLE: Preparation of indanyl isoxazoloquinolinones as multidrug resistance protein (MRP1) inhibitors  
 INVENTOR(S): Gruber, Joseph Michael; Hollinshead, Sean Patrick; Norman, Bryan Hurst; Wilson, Joseph Wendell  
 PATENT ASSIGNEE(S): Eli Lilly and Company, USA  
 SOURCE: PCT Int. Appl., 52 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9951236	A1	19991014	WO 1999-US7615	19990407
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2327452	AA	19991014	CA 1999-2327452	19990407
AU 9935502	A1	19991025	AU 1999-35502	19990407
BR 9909446	A	20001212	BR 1999-9446	19990407
EP 1067932	A1	20010117	EP 1999-917359	19990407
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
TR 200002804	T2	20010221	TR 2000-200002804	19990407
US 6221876	B1	20010424	US 2000-646063	20000913
NO 200005041	A	20001006	NO 2000-5041	20001006
PRIORITY APPLN. INFO.:			US 1998-81088P	P 19980408

OTHER SOURCE(S):  
GI

MARPAT 131:286506



AB The title compds. (I) [where R = H, COR<sub>1</sub>, or SO<sub>2</sub>R<sub>2</sub>; R<sub>1</sub> = (un)substituted alkyl, (un)substituted aryl, furanyl, indolyl, 5-Me-isoxazolyl, or (un)substituted amino; R<sub>2</sub> = 3,5-di-Me-isoxazolyl or (un)substituted Ph] were prepared as inhibitors of 190 kDa multidrug resistance protein (MRP1) for inhibiting resistant neoplasms (14 specific neoplasm types claimed). Selected compds. were prepared using solution and solid phase synthetic methods. Representative compds. demonstrated a significant reversal of MRP1 multiple drug resistance, and many compds. gave very significant enhancement of oncolytic agents (no data). A large majority of the compds. tested were also said to have displayed a significant degree of selective inhibition of the HL60/ADR cell line over the HL60/VCR cell line in an assay for reversal of MRP1-mediated doxorubicin and vincristine resistance (no data).

IT 246153-44-6P 246153-46-8P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of isoxazoloquinolinones as MRP1 inhibitors for inhibiting resistant neoplasm)

RN 246153-44-6 CAPLUS

CN Carbamic acid, [(1R,2R)-6-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 246153-46-8 CAPLUS

CN Isoxazolo[4,3-c]quinolin-4(5H)-one, 5-[(2R,3R)-3-amino-2,3-dihydro-2-hydroxy-1H-inden-5-yl]-9-chloro-3-methyl-, rel-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)


CRN 246153-45-7  
CMF C20 H16 Cl N3 O3

Relative stereochemistry.




CM 2

CRN 76-05-1  
CMF C2 H F3 O2




IT 246153-40-2P 246153-41-3P 246153-42-4P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(target compound; preparation of isoxazoloquinolinones as MRP1 inhibitors for inhibiting resistant neoplasm)  
RN 246153-40-2 CAPLUS  
CN 3-Isioxazolecarboxamide, N-[(1R,2R)-6-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]-5-methyl-, rel-(9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 246153-41-3 CAPLUS  
CN Benzamide, N-[(1R,2R)-6-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]-3,4,5-trimethoxy-, rel-(9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 246153-42-4 CAPLUS  
CN Benzamide, N-[6-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]-3,4,5-trimethoxy- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L30 ANSWER 23 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 1999:659233 CAPLUS <<LOGINID::20060919>>  
DOCUMENT NUMBER: 131:286505  
TITLE: Preparation of isoxazoloquinolinones as multidrug resistance protein (MRP1) inhibitors  
INVENTOR(S): Gruber, Joseph Michael; Kroin, Julian Stanley; Norman, Bryan Hurst  
PATENT ASSIGNEE(S): Eli Lilly and Company, USA  
SOURCE: PCT Int. Appl., 126 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9951228	A1	19991014	WO 1999-US7613	19990407
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,				

JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,  
 MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,  
 TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW  
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,  
 ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,  
 CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2327617	AA	19991014	CA 1999-2327617	19990407
AU 9934769	A1	19991025	AU 1999-34769	19990407
TR 200002851	T2	20001221	TR 2000-200002851	19990407
BR 9910112	A	20001226	BR 1999-10112	19990407
EP 1067928	A1	20010117	EP 1999-916456	19990407

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE,  
 SI, LT, LV, FI, RO



US 6369070	B1	20020409	US 2000-646062	20000913
HR 2000000646	A1	20010630	HR 2000-646	20001003
NO 2000005023	A	20001205	NO 2000-5023	20001005

PRIORITY APPLN. INFO.:

US 1998-81080P	P	19980408
WO 1999-US7613	W	19990407

OTHER SOURCE(S): MARPAT 131:286505

GI



AB The title compds. (I) [where R = (un)substituted amino(alkyl) or aminoethoxy, or (CH<sub>2</sub>)<sub>m</sub>R<sub>3</sub>; m and m' = independently 0, 1, or 2; R<sub>3</sub> = H, OH, alkoxy, amino ester, amino acid, or (un)substituted amino; R' = H, OH, or (un)substituted alkoxy] were prepared as inhibitors of 190 kDa multidrug resistance protein (MRP1) for inhibiting resistant neoplasms (14 specific neoplasm types claimed). Selected invention compds. were prepared via solution and solid phase combinatorial synthetic methods. For example, 3-(2-chloro-6-fluorophenyl)-5-methyl-4-isoxazoyl chloride was coupled with N-(5-methylisoxaz-3-oyl)-3-aminobenzylamine to form the amide followed by treatment with NaOH to yield the cyclized title compound (II). Several general procedures using substituted polystyrene resins for combinatorial preparation of title compds. were given. Representative compds. demonstrated significant reversal of MRP1 multiple drug resistance, and many compds.

gave significant enhancement of oncolytic agent activities (no data). A large majority of the compds. tested were also said to have displayed a significant degree of selective inhibition of the HL60/ADR cell line over the HL60/VCR cell line in an assay for reversal of MRP1-mediated doxorubicin and vincristine resistance (no data).


IT 246240-18-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of isoxazoloquinolinones as MRP1 inhibitors for inhibiting resistant neoplasm)

RN 246240-18-6 CAPLUS

CN Isoxazolo[4,3-c]quinolin-4(5H)-one, 9-chloro-3-methyl-5-[(3-nitrophenyl)methyl]- (9CI) (CA INDEX NAME)



IT 246240-20-0 246240-21-1 246240-22-2

246240-23-3 246240-24-4 246240-25-5

246240-26-6 246240-27-7 246240-29-9


246240-30-2 246240-32-4

RL: RCT (Reactant); RACT (Reactant or reagent)

(reactant; preparation of isoxazoloquinolinones as MRP1 inhibitors for inhibiting resistant neoplasm)


RN 246240-20-0 CAPLUS

CN Benzeneacetyl chloride, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)- (9CI) (CA INDEX NAME)




RN 246240-21-1 CAPLUS

CN Benzeneacetyl chloride, 2-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)- (9CI) (CA INDEX NAME)




RN 246240-22-2 CAPLUS

CN Benzenepropanoyl chloride, 2-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl) - (9CI) (CA INDEX NAME)




RN 246240-23-3 CAPLUS

CN Benzoyl chloride, 4-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl) - (9CI) (CA INDEX NAME)




RN 246240-24-4 CAPLUS

CN Benzeneacetyl chloride, 4-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl) - (9CI) (CA INDEX NAME)




RN 246240-25-5 CAPLUS

CN Benzeneacetyl chloride, 5-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-2-hydroxy- (9CI) (CA INDEX NAME)




RN 246240-26-6 CAPLUS

CN Benzeneacetyl chloride, 5-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-2-methoxy- (9CI) (CA INDEX NAME)




RN 246240-27-7 CAPLUS

CN Benzeneacetyl chloride, 5-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-2-(phenylmethoxy)- (9CI) (CA INDEX NAME)




RN 246240-29-9 CAPLUS

CN Benzeneacetyl chloride, 5-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-2-(cyclohexylmethoxy)- (9CI) (CA INDEX NAME)




RN 246240-30-2 CAPLUS

CN Isoxazolo[4,3-c]quinolin-4(5H)-one, 9-chloro-3-methyl-5-[3-[(methylamino)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 246240-32-4 CAPLUS

CN Benzoyl chloride, 2-[2-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)ethyl]- (9CI) (CA INDEX NAME)




IT 246238-17-5P 246238-18-6P 246238-19-7P  
 246238-20-0P 246238-21-1P 246238-27-7P  
 246238-28-8P 246238-36-8P 246238-37-9P  
 246238-38-0P 246238-40-4P 246238-45-9P  
 246239-70-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(target compound; preparation of isoxazoloquinolinones as MRP1 inhibitors for inhibiting resistant neoplasm)


RN 246238-17-5 CAPLUS

CN Isoxazolo[4,3-c]quinolin-4(5H)-one, 5-(3-acetylphenyl)-9-chloro-3-methyl-(9CI) (CA INDEX NAME)



RN 246238-18-6 CAPLUS


CN Isoxazolo[4,3-c]quinolin-4(5H)-one, 5-(3-aminophenyl)-9-chloro-3-methyl-(9CI) (CA INDEX NAME)



RN 246238-19-7 CAPLUS


CN Carbamic acid, [[3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-

yl)phenyl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 246238-20-0 CAPLUS

CN Isoxazolo[4,3-c]quinolin-4(5H)-one, 5-[3-(aminomethyl)phenyl]-9-chloro-3-methyl- (9CI) (CA INDEX NAME)




RN 246238-21-1 CAPLUS

CN Benzamide, N-[[3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)phenyl)methyl]-3,5-dimethoxy-4-(phenylmethoxy)- (9CI) (CA INDEX NAME)




RN 246238-27-7 CAPLUS

CN Carbamic acid, [2-[3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)phenoxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 246238-28-8 CAPLUS


CN Isoxazolo[4,3-c]quinolin-4(5H)-one, 5-[3-(2-aminoethoxy)phenyl]-9-chloro-3-methyl- (9CI) (CA INDEX NAME)



RN 246238-36-8 CAPLUS

CN L-Glutamine, N-[2-[3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)phenoxy]ethyl]-N2-[(1,1-dimethylethoxy)carbonyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 246238-37-9 CAPLUS

CN L-Glutamine, N-[2-[3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)phenoxy]ethyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 246238-38-0 CAPLUS


CN L-Glutamine, N- [2- [3- (9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)phenoxy]ethyl] -N2- [(1,1-dimethylethoxy)carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 246238-40-4 CAPLUS

CN Benzoic acid, 3- (9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl) - , ethyl ester (9CI) (CA INDEX NAME)




RN 246238-45-9 CAPLUS

CN Benzeneacetic acid, 3- (9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)- (9CI) (CA INDEX NAME)



RN 246239-70-3 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-[4-[(dipropylamino)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



IT 246238-13-1P 246238-14-2P 246238-15-3P  
 246238-16-4P 246238-22-2P 246238-23-3P  
 246238-24-4P 246238-25-5P 246238-26-6P  
 246238-29-9P 246238-30-2P 246238-32-4P  
 246238-33-5P 246238-34-6P 246238-35-7P  
 246238-39-1P 246238-41-5P 246238-42-6P  
 246238-43-7P 246238-44-8P 246238-46-0P  
 246238-47-1P 246238-48-2P 246238-49-3P  
 246238-50-6P 246238-52-8P 246238-53-9P  
 246238-54-0P 246238-55-1P 246238-56-2P  
 246238-57-3P 246238-58-4P 246238-59-5P  
 246238-60-8P 246238-61-9P 246238-62-0P  
 246238-64-2P 246238-66-4P 246238-68-6P  
 246238-70-0P 246238-71-1P 246238-73-3P  
 246238-74-4P 246238-75-5P 246238-76-6P  
 246238-77-7P 246238-78-8P 246238-80-2P  
 246238-81-3P 246238-82-4P 246238-83-5P  
 246238-84-6P 246238-85-7P 246238-86-8P  
 246238-87-9P 246238-88-0P 246238-89-1P  
 246238-90-4P 246238-91-5P 246238-92-6P  
 246238-93-7P 246238-94-8P 246238-95-9P  
 246238-96-0P 246238-97-1P 246238-98-2P  
 246238-99-3P 246239-00-9P 246239-01-0P  
 246239-02-1P 246239-03-2P 246239-04-3P  
 246239-05-4P 246239-06-5P 246239-07-6P  
 246239-08-7P 246239-09-8P 246239-10-1P  
 246239-11-2P 246239-12-3P 246239-13-4P  
 246239-14-5P 246239-15-6P 246239-16-7P  
 246239-17-8P 246239-18-9P 246239-19-0P  
 246239-20-3P 246239-21-4P 246239-22-5P  
 246239-23-6P 246239-24-7P 246239-25-8P

246239-28-1P 246239-29-2P 246239-30-5P  
 246239-31-6P 246239-32-7P 246239-33-8P  
 246239-34-9P 246239-35-0P 246239-36-1P  
 246239-37-2P 246239-38-3P 246239-39-4P  
 246239-40-7P 246239-41-8P 246239-42-9P  
 246239-43-0P 246239-45-2P 246239-46-3P  
 246239-47-4P 246239-48-5P 246239-49-6P  
 246239-50-9P 246239-51-0P 246239-52-1P  
 246239-53-2P 246239-54-3P 246239-55-4P  
 246239-56-5P 246239-57-6P 246239-58-7P  
 246239-59-8P 246239-60-1P 246239-61-2P  
 246239-62-3P 246239-63-4P 246239-65-6P  
 246239-66-7P 246239-67-8P 246239-68-9P  
 246239-69-0P 246239-71-4P 246239-72-5P  
 246239-73-6P 246239-74-7P 246239-75-8P  
 246239-76-9P 246239-77-0P 246239-79-2P  
 246239-80-5P 246239-82-7P 246239-83-8P  
 246239-84-9P 246239-85-0P 246239-86-1P  
 246239-87-2P 246239-88-3P 246239-89-4P  
 246239-90-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(target compound; preparation of isoxazoloquinolinones as MRP1 inhibitors

for

inhibiting resistant neoplasm)


RN 246238-13-1 CAPLUS

CN 3-Isoxazolecarboxamide, N-[[3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)phenyl)methyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 246238-14-2 CAPLUS

CN 3-Isoxazolecarboxamide, N-[[2-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)phenyl)methyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 246238-15-3 CAPLUS

CN 3-Isioxazolecarboxamide, N-[[4-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)phenyl)methyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 246238-16-4 CAPLUS

CN 4-Isioxazolecarboxamide, N-[[3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)phenyl)methyl]-5-methyl-3-phenyl- (9CI) (CA INDEX NAME)




RN 246238-22-2 CAPLUS

CN Benzamide, N-[[3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)phenyl)methyl]-3,4,5-trimethoxy- (9CI) (CA INDEX NAME)




RN 246238-23-3 CAPLUS

CN Benzamide, N-[[3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)phenyl)methyl]-4-hydroxy-3,5-dimethoxy- (9CI) (CA INDEX NAME)




RN 246238-24-4 CAPLUS

CN Urea, N-[[3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)phenyl]methyl]-N'-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 246238-25-5 CAPLUS

CN Thiourea, N-[[3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)phenyl]methyl]-N'-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 246238-26-6 CAPLUS

CN Benzenesulfonamide, N-[[3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)phenyl]methyl]-4-methoxy- (9CI) (CA INDEX NAME)




RN 246238-29-9 CAPLUS

CN Benzamide, N-[2-[3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)phenoxy]ethyl]- (9CI) (CA INDEX NAME)




RN 246238-30-2 CAPLUS

CN Benzamide, N-[2-[3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)phenoxy]ethyl]-3,4,5-trimethoxy- (9CI) (CA INDEX NAME)




RN 246238-32-4 CAPLUS

CN Acetamide, N-[2-[3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)phenoxy]ethyl]- (9CI) (CA INDEX NAME)




RN 246238-33-5 CAPLUS

CN Methanesulfonamide, N-[2-[3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)phenoxy]ethyl]- (9CI) (CA INDEX NAME)




RN 246238-34-6 CAPLUS

CN Acetamide, N-[4-[[[2-[3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)phenoxy]ethyl]amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 246238-35-7 CAPLUS


CN 3(2H)-Benzoxazolepropanamide, N-[2-[3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)phenoxy]ethyl]-2-oxo- (9CI) (CA INDEX NAME)



RN 246238-39-1 CAPLUS


CN L-Glutamine, N-[2-[3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)phenoxy]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 246238-41-5 CAPLUS

CN Benzoic acid, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)- (9CI) (CA INDEX NAME)




RN 246238-42-6 CAPLUS

CN Benzoic acid, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-, methyl ester (9CI) (CA INDEX NAME)




RN 246238-43-7 CAPLUS

CN Benzamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 246238-44-8 CAPLUS

CN Benzamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-[(3,4,5-trimethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 246238-46-0 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-phenyl- (9CI) (CA INDEX NAME)




RN 246238-47-1 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 246238-48-2 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 246238-49-3 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 246238-50-6 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-[(3,4,5-trimethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 246238-52-8 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 246238-53-9 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-methyl- (9CI) (CA INDEX NAME)




RN 246238-54-0 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(cyclohexylmethyl)- (9CI) (CA INDEX NAME)




RN 246238-55-1 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 246238-56-2 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 246238-57-3 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(pentafluorophenyl)- (9CI) (CA INDEX NAME)




RN 246238-58-4 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-[4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 246238-59-5 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(3,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 246238-60-8 CAPLUS

CN Benzeneacetamide, N-1,3-benzodioxol-5-yl-3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)- (9CI) (CA INDEX NAME)




RN 246238-61-9 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 246238-62-0 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 246238-64-2 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 246238-66-4 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 246238-68-6 CAPLUS

CN Benzoic acid, 4-[[[3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)phenyl]acetyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 246238-70-0 CAPLUS

CN Carbamic acid, [1-[3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)phenyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 246238-71-1 CAPLUS

CN Isoxazolo[4,3-c]quinolin-4(5H)-one, 9-chloro-3-methyl-5-[3-[1-[(2-pyridinylmethyl)amino]ethyl]phenyl]- (9CI) (CA INDEX NAME)




RN 246238-73-3 CAPLUS

CN Isoxazolo[4,3-c]quinolin-4(5H)-one, 9-chloro-5-[3-[1-[[[4-(dimethylamino)phenyl]methyl]amino]ethyl]phenyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 246238-74-4 CAPLUS

CN Glycine, N-[1-[3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)phenyl]ethyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 246238-75-5 CAPLUS

CN Isoxazolo[4,3-c]quinolin-4(5H)-one, 9-chloro-3-methyl-5-[3-[1-(4-morpholinyl)ethyl]phenyl]- (9CI) (CA INDEX NAME)




RN 246238-76-6 CAPLUS

CN Isoxazolo[4,3-c]quinolin-4(5H)-one, 9-chloro-3-methyl-5-[3-[1-[[2-(1-piperidinyl)ethyl]amino]ethyl]phenyl]- (9CI) (CA INDEX NAME)




RN 246238-77-7 CAPLUS

CN Isoxazolo[4,3-c]quinolin-4(5H)-one, 9-chloro-5-[3-[1-[(2-furanylmethyl)amino]ethyl]phenyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 246238-78-8 CAPLUS

CN Isoxazolo[4,3-c]quinolin-4(5H)-one, 9-chloro-5-[3-[1-[(2-methoxyethyl)amino]ethyl]phenyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 246238-80-2 CAPLUS


CN Isoxazolo[4,3-c]quinolin-4(5H)-one, 9-chloro-3-methyl-5-[3-[1-[(phenylmethyl)amino]ethyl]phenyl]- (9CI) (CA INDEX NAME)




RN 246238-81-3 CAPLUS  
 CN Isoxazolo[4,3-c]quinolin-4(5H)-one, 9-chloro-5-[3-[1-[(3,5-dimethoxyphenyl)methyl]amino]ethyl]phenyl]-3-methyl- (9CI) (CA INDEX NAME)



RN 246238-82-4 CAPLUS  
 CN Isoxazolo[4,3-c]quinolin-4(5H)-one, 9-chloro-3-methyl-5-[3-[1-[(3,5-dimethoxyphenyl)methyl]amino]ethyl]phenyl]- (9CI) (CA INDEX NAME)




RN 246238-83-5 CAPLUS  
 CN Isoxazolo[4,3-c]quinolin-4(5H)-one, 9-chloro-3-methyl-5-[3-[1-[(3,5-dimethoxyphenyl)methyl]amino]ethyl]phenyl]- (9CI) (CA INDEX NAME)




RN 246238-84-6 CAPLUS

CN Acetamide, N-[2-[[1-[3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)phenyl]ethyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 246238-85-7 CAPLUS

CN Isoxazolo[4,3-c]quinolin-4(5H)-one, 9-chloro-5-[3-[1-(cyclohexylamino)ethyl]phenyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 246238-86-8 CAPLUS

CN Isoxazolo[4,3-c]quinolin-4(5H)-one, 9-chloro-3-methyl-5-[3-[1-[(1-methylethyl)amino]ethyl]phenyl]- (9CI) (CA INDEX NAME)




RN 246238-87-9 CAPLUS

CN Isoxazolo[4,3-c]quinolin-4(5H)-one, 9-chloro-5-[3-[1-[(2,6-dimethoxyphenyl)methyl]amino]ethyl]phenyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 246238-88-0 CAPLUS

CN Isoxazolo[4,3-c]quinolin-4(5H)-one, 9-chloro-3-methyl-5-[3-[1-[[4-(trifluoromethyl)phenyl]methyl]amino]ethyl]phenyl]- (9CI) (CA INDEX NAME)




RN 246238-89-1 CAPLUS

CN Butanoic acid, 3-[[1-[3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)phenyl]ethyl]amino]-, 1-methylethyl ester (9CI) (CA INDEX NAME)




RN 246238-90-4 CAPLUS  
 CN Phenylalanine, N-[1-[3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)phenyl]ethyl]-4-(trifluoromethyl)-, 1-methylethyl ester (9CI)  
 (CA INDEX NAME)




RN 246238-91-5 CAPLUS  
 CN L-Valine, N-[1-[3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)phenyl]ethyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 246238-92-6 CAPLUS  
 CN L-Tryptophan, N-[1-[3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)phenyl]ethyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 246238-93-7 CAPLUS

CN L-Aspartic acid, N-[1-[3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)phenyl]ethyl]-, bis(1-methylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 246238-94-8 CAPLUS


CN D-Proline, 1-[1-[3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)phenyl]ethyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 246238-95-9 CAPLUS


CN Benzenesulfonamide, 4-[[[1-[3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)phenyl]ethyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 246238-96-0 CAPLUS


CN L-Methionine, N-[1-[3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)phenyl]ethyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 246238-97-1 CAPLUS


CN Glycine, N-[1-[3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)phenyl]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 246238-98-2 CAPLUS

CN Butanoic acid, 3-[[1-[3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)phenyl]ethyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 246238-99-3 CAPLUS

CN L-Tryptophan, N-[1-[3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)phenyl]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 246239-00-9 CAPLUS

CN L-Valine, N-[1-[3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)phenyl]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 246239-01-0 CAPLUS

CN L-Aspartic acid, N-[1-[3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)phenyl]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 246239-02-1 CAPLUS

CN D-Proline, 1-[1-[3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)phenyl]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 246239-03-2 CAPLUS

CN Benzeneacetamide, N-bicyclo[2.2.1]hept-2-yl-3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)- (9CI) (CA INDEX NAME)




RN 246239-04-3 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(2-phenylpropyl)- (9CI) (CA INDEX NAME)



RN 246239-05-4 CAPLUS


CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-1H-pyrazol-3-yl- (9CI) (CA INDEX NAME)



RN 246239-06-5 CAPLUS


CN L-Glutamic acid, N-[[3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)phenyl]acetyl]-, dimethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 246239-07-6 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-[(3,5-dimethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 246239-08-7 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(4-cyclohexylphenyl)- (9CI) (CA INDEX NAME)




RN 246239-09-8 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-[2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 246239-10-1 CAPLUS

CN Carbamic acid, [2-[[[3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)phenyl]acetyl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 246239-11-2 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)




RN 246239-12-3 CAPLUS

CN Isoxazolo[4,3-c]quinolin-4(5H)-one, 9-chloro-3-methyl-5-[3-(2-naphthalenylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 246239-13-4 CAPLUS

CN Isoxazolo[4,3-c]quinolin-4(5H)-one, 5-[(3-aminophenyl)methyl]-9-chloro-3-methyl- (9CI) (CA INDEX NAME)




RN 246239-14-5 CAPLUS

CN Benzamide, N-[3-[(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)methyl]phenyl]-3,4,5-trimethoxy- (9CI) (CA INDEX NAME)




RN 246239-15-6 CAPLUS

CN Benzamide, 4-(aminosulfonyl)-N-[[3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 246239-16-7 CAPLUS

CN Benzamide, N-[[3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)phenyl]methyl]-4-[(dipropylamino)sulfonyl]- (9CI) (CA INDEX NAME)




RN 246239-17-8 CAPLUS

CN Propanamide, 3-[[4-(aminosulfonyl)phenyl]amino]-N-[[3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 246239-18-9 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(6-methoxy-8-quinolinyl)- (9CI) (CA INDEX NAME)




RN 246239-19-0 CAPLUS

CN Benzeneacetamide, N-[4-(aminosulfonyl)phenyl]-3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)- (9CI) (CA INDEX NAME)




RN 246239-20-3 CAPLUS

CN Benzeneacetamide, N-[[4-(aminosulfonyl)phenyl]methyl]-3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)- (9CI) (CA INDEX NAME)




RN 246239-21-4 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 246239-22-5 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 246239-23-6 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(2,3-dimethylphenyl)- (9CI) (CA INDEX NAME)




RN 246239-24-7 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(2,4-dimethylphenyl)- (9CI) (CA INDEX NAME)




RN 246239-25-8 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(2,5-dimethylphenyl)- (9CI) (CA INDEX NAME)




RN 246239-28-1 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(2,6-dimethylphenyl)- (9CI) (CA INDEX NAME)




RN 246239-29-2 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(3,4-dimethylphenyl)- (9CI) (CA INDEX NAME)




RN 246239-30-5 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(3,5-dimethylphenyl)- (9CI) (CA INDEX NAME)




RN 246239-31-6 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)




RN 246239-32-7 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(2,4,5-trimethylphenyl)- (9CI) (CA INDEX NAME)




RN 246239-33-8 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 246239-34-9 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 246239-35-0 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(2,3-dimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 246239-36-1 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(2,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 246239-37-2 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(2,5-dimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 246239-38-3 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(4-hydroxy-3,5-dimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 246239-39-4 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(2-methoxy-6-methylphenyl)- (9CI) (CA INDEX NAME)




RN 246239-40-7 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(5-methoxy-2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 246239-41-8 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(4-methoxy-2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 246239-42-9 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(2-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 246239-43-0 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(2-methoxy-5-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 246239-45-2 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(2-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 246239-46-3 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(3-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 246239-47-4 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(3,5-dinitrophenyl)- (9CI) (CA INDEX NAME)




RN 246239-48-5 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(4-methoxy-2-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 246239-49-6 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(2-fluorophenyl)- (9CI). (CA INDEX NAME)




RN 246239-50-9 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 246239-51-0 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(2,3-difluorophenyl)- (9CI) (CA INDEX NAME)




RN 246239-52-1 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(2,4-difluorophenyl)- (9CI) (CA INDEX NAME)




RN 246239-53-2 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(2,5-difluorophenyl)- (9CI) (CA INDEX NAME)




RN 246239-54-3 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(2,6-difluorophenyl)- (9CI) (CA INDEX NAME)




RN 246239-55-4 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(3,4-difluorophenyl)- (9CI) (CA INDEX NAME)




RN 246239-56-5 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(3,5-difluorophenyl)- (9CI) (CA INDEX NAME)




RN 246239-57-6 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(2,3,4-trifluorophenyl)- (9CI) (CA INDEX NAME)




RN 246239-58-7 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(2,3,6-trifluorophenyl)- (9CI) (CA INDEX NAME)




RN 246239-59-8 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(2,4,5-trifluorophenyl)- (9CI) (CA INDEX NAME)




RN 246239-60-1 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)




RN 246239-61-2 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(2,3,4,5-tetrafluorophenyl)- (9CI) (CA INDEX NAME)




RN 246239-62-3 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(2,3,4,6-tetrafluorophenyl)- (9CI) (CA INDEX NAME)




RN 246239-63-4 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(2,3,5,6-tetrafluorophenyl)- (9CI) (CA INDEX NAME)




RN 246239-65-6 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(3-fluoro-4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 246239-66-7 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(4-(1,1-dimethylethyl)phenyl)- (9CI) (CA INDEX NAME)




RN 246239-67-8 CAPLUS

CN Benzeneacetamide, N-(4-acetylphenyl)-3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)- (9CI) (CA INDEX NAME)




RN 246239-68-9 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(4-cyanophenyl)- (9CI) (CA INDEX NAME)




RN 246239-69-0 CAPLUS

CN Benzeneacetamide, N-[4-(aminocarbonyl)phenyl]-3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)- (9CI) (CA INDEX NAME)




RN 246239-71-4 CAPLUS

CN Benzeneacetamide, N-[3,5-bis(trifluoromethyl)phenyl]-3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)- (9CI) (CA INDEX NAME)




RN 246239-72-5 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-[3-methoxy-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 246239-73-6 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-[5-(1,1-dimethylethyl)-2-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 246239-74-7 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-2-naphthalenyl- (9CI) (CA INDEX NAME)




RN 246239-75-8 CAPLUS

CN Benzeneacetamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-methyl-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 246239-76-9 CAPLUS

CN Benzeneacetamide, 2-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 246239-77-0 CAPLUS

CN Benzenepropanamide, 2-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 246239-79-2 CAPLUS

CN Benzamide, 4-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 246239-80-5 CAPLUS

CN Benzeneacetamide, 4-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 246239-82-7 CAPLUS

CN Benzeneacetamide, 5-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-2-hydroxy-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 246239-83-8 CAPLUS

CN Benzeneacetamide, 5-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-2-methoxy-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 246239-84-9 CAPLUS

CN Benzeneacetamide, 5-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-2-(phenylmethoxy)-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 246239-85-0 CAPLUS

CN Benzeneacetamide, 5-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-2-(cyclohexylmethoxy)-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 246239-86-1 CAPLUS

CN Benzamide, N-[[3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)phenyl]methyl]-3,4,5-trimethoxy-N-methyl- (9CI) (CA INDEX NAME)




RN 246239-87-2 CAPLUS

CN Benzamide, N-[[3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)phenyl]methyl]-3,5-dimethoxy-4-methyl- (9CI) (CA INDEX NAME)




RN 246239-88-3 CAPLUS


CN Benzamide, N-[3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)phenyl]-3,4,5-trimethoxy- (9CI) (CA INDEX NAME)



RN 246239-89-4 CAPLUS  
 CN Benzeneacetamide, N-[3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)phenyl]-3,4,5-trimethoxy- $\alpha$ -oxo- (9CI) (CA INDEX NAME)




RN 246239-90-7 CAPLUS  
 CN Benzamide, 2-[2-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)ethyl]-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L30 ANSWER 24 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 1998:340789 CAPLUS <<LOGINID::20060919>>  
 DOCUMENT NUMBER: 129:41062  
 TITLE: Conversion of 3-hydroxy-1,2,3,4-tetrahydroquinoline-2,4-diones to 2,3a,4,5-tetrahydrofuro[2,3-c]quinoline-


2,4-diones via an intramolecular wittig reaction  
 AUTHOR(S): Klasek, Antonin; Kafka, Stanislav  
 CORPORATE SOURCE: Department of Chemistry and Environmental Technology,  
 Faculty of Technology, Technical University of Brno,  
 Zlin, CZ-762 72, Czech Rep.  
 SOURCE: Journal of Heterocyclic Chemistry (1998), 35(2),  
 307-311  
 CODEN: JHTCAD; ISSN: 0022-152X  
 PUBLISHER: HeteroCorporation  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 AB The preparation of 2,3a,4,5-tetrahydrofuro[2,3-c]quinoline-2,4-diones starting  
 from 3-hydroxy-1,2,3,4-tetrahydroquinoline-2,4-diones and using the  
 reaction path via bromoacetyl derivs. and triphenylphosphonioacetyl  
 derivs. of the initial substances is described.  
 IT 186766-36-9P 186766-38-1P 186766-39-2P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (tetrahydrofuro[2,3-c]quinoline-2,4-diones preparation via an intramol.  
 wittig reaction)  
 RN 186766-36-9 CAPLUS  
 CN Furo[2,3-c]quinoline-2,4(3aH,5H)-dione, 3a-butyl-5-phenyl- (9CI) (CA  
 INDEX NAME)



RN 186766-38-1 CAPLUS  
 CN Furo[2,3-c]quinoline-2,4(3aH,5H)-dione, 5-phenyl-3a-(phenylmethyl)- (9CI)  
 (CA INDEX NAME)




RN 186766-39-2 CAPLUS  
 CN Furo[2,3-c]quinoline-2,4(3aH,5H)-dione, 3a,5-diphenyl- (9CI) (CA INDEX  
 NAME)




REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L30 ANSWER 25 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 1997:458953 CAPLUS <<LOGINID::20060919>>  
 DOCUMENT NUMBER: 127:161731  
 TITLE: Thermal reactions of 2-(2-oxo-3-nitro-4-quinolinyl)malonates  
 AUTHOR(S): Taubl, A. Elisabeth; Stadlbauer, Wolfgang  
 CORPORATE SOURCE: Institute of Organic Chemistry, Karl-Franzens-University Graz, Graz, A-8010, Austria  
 SOURCE: Journal of Heterocyclic Chemistry (1997), 34(3), 989-991  
 CODEN: JHTCAD; ISSN: 0022-152X  
 PUBLISHER: HeteroCorporation  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 127:161731  
 GI




I




II

AB Depending on the ester substituent, di-Et 2-(3-nitro-2-oxo-4-quinolinyl)malonates I [R1 = H, R2 = Me, Ph, R3 = Et; R1R2 = (CH2)3, R3 = Et] give upon thermolysis Et 2-(3-nitro-2-oxo-4-quinolinyl)acetates, whereas di-Me 2-(3-nitro-2-oxo-4-quinolinyl)malonates I (R3 = Me) cyclize to give 1-methoxycarbonylisoxazolo[3,4-c]quinolin-4(5H)-ones II. The necessary reaction conditions can be obtained easily with the help of differential scanning calorimetry.  
 IT 193673-49-3P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation and thermal rearrangement of (oxonitroquinolinyl)malonates)  
 RN 193673-49-3 CAPLUS  
 CN Isoxazolo[3,4-c]quinoline-1-carboxylic acid, 4,5-dihydro-4-oxo-5-phenyl-, methyl ester (9CI) (CA INDEX NAME)




REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L30 ANSWER 26 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 1997:81516 CAPLUS <<LOGINID::20060919>>  
 DOCUMENT NUMBER: 126:144096  
 TITLE: Reaction of 3-hydroxy-1,2,3,4-tetrahydroquinoline-2,4-diones with ethyl (triphenylphosphoranylidene)acetate  
 AUTHOR(S): Kafka, Stanislav; Kovar, Michal; Klasek, Antonin; Kappe, Thomas  
 CORPORATE SOURCE: Dep. Chem. Environ. Technol., Tech. Univ. Brno, Zlin, 762 72, Czech Rep.  
 SOURCE: Journal of Heterocyclic Chemistry (1996), 33(6), 1977-1982  
 CODEN: JHTCAD; ISSN: 0022-152X  
 PUBLISHER: HeteroCorporation  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 AB The Wittig reaction of 3-hydroxy-1,2,3,4-tetrahydroquinoline-2,4-diones with Et (triphenylphosphoranylidene)acetate proceeds stereoselectively to give E-4-carbethoxymethylene-1,2,3,4-tetrahydro-2-quinolones, which were hydrolyzed to corresponding acids. Butenolides were detected and, in some cases, isolated as a minor product of the Wittig reaction.  
 IT 186766-36-9P 186766-38-1P 186766-39-2P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of)  
 RN 186766-36-9 CAPLUS  
 CN Furo[2,3-c]quinoline-2,4(3aH,5H)-dione, 3a-butyl-5-phenyl- (9CI) (CA INDEX NAME)



RN 186766-38-1 CAPLUS  
 CN Furo[2,3-c]quinoline-2,4(3aH,5H)-dione, 5-phenyl-3a-(phenylmethyl)- (9CI) (CA INDEX NAME)





RN 186766-39-2 CAPLUS  
 CN Furo[2,3-c]quinoline-2,4(3aH,5H)-dione, 3a,5-diphenyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L30 ANSWER 27 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 1995:300869 CAPLUS <<LOGINID::20060919>>  
 DOCUMENT NUMBER: 122:160521  
 TITLE: Organic azides in heterocyclic synthesis. Part 19.  
 Synthesis of oxazolo[4,5-c]quinolones by thermolytic degradation of 4-azido-2(1H)-quinolones  
 AUTHOR(S): Steinschifter, Waltraud; Fiala, Werner; Stadlbauer, Wolfgang  
 CORPORATE SOURCE: Inst. Org. Chem., Karl-Franzens-Univ. Graz, Graz, A-8010, Australia  
 SOURCE: Journal of Heterocyclic Chemistry (1994), 31(6), 1647-52  
 CODEN: JHTCAD; ISSN: 0022-152X  
 PUBLISHER: HeteroCorporation  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 122:160521  
 GI




AB 4-Azido-2(1H)-quinolones I [R1 = Me, Ph, H, R2 = H; R1R2 = (CH2)3] are thermolyzed in the presence of carboxylic acids R3CO2H (R3 = Me, Et, Ph) and polyphosphoric acid to yield oxazolo[4,5-c]quinolones II. Formation of other possible isomeric ring closure products such as oxazolo[5,4-c]quinolones or isoxazolo[4,3-c]quinolones could be excluded by independent syntheses.

IT 161371-33-1P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of oxazoloquinolones by thermolytic cyclization of azidoquinolones with carboxylic acids)

RN 161371-33-1 CAPLUS

CN Isoxazolo[4,3-c]quinolin-4(5H)-one, 3-methyl-5-phenyl- (9CI) (CA INDEX NAME)



L30 ANSWER 28 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1993:625948 CAPLUS <<LOGINID::20060919>>

DOCUMENT NUMBER: 119:225948

TITLE: Preparation of pyrazoloquinoline and pyrazolonaphthyridine derivatives

INVENTOR(S): Hashimoto, Kinji; Tomoyasu, Takahiro; Inoe, Makoto; Kuwabara, Toshiko; Sugimoto, Yukio; Kamisako, Takuji

PATENT ASSIGNEE(S): Otsuka Pharma Co Ltd, Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 36 pp.  
 CODEN: JKXXAF

DOCUMENT TYPE: Patent


LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 05132484	A2	19930528	JP 1992-106477	19920424
PRIORITY APPLN. INFO.:			JP 1991-97439	A1 19910426
OTHER SOURCE(S):	MARPAT 119:225948			

GI



I


AB Title compds. I (R1 = H, alkyl, alkenyl; R2 = H, alkyl, Ph; R3 = H, halo; R4, R5 = H, alkanoyl, alkylsulfonyl; Y = CH, N; dotted line in pyrazole ring indicated two double bonds), useful as inflammation inhibitors, immunomodulators, analgesics, and antipyretics (no data), were prepared. Thus, 3-cyano-1,2-dihydro-4-hydroxy-1-methyl-2-oxoquinoline was treated with POCl<sub>3</sub> in diethylaniline to give 4-chloro-3-cyano-1,2-dihydro-1-methyl-2-oxoquinoline, which was refluxed with MeNHNH<sub>2</sub> in MeOH to give 3-amino-1,5-dimethyl-1H,5H-pyrazolo[4,3-c]quinolin-4-one.

IT 150617-01-9P 150617-02-0P 150617-03-1P  
150617-04-2P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of, as inflammation inhibitor, antipyretic, and analgesic)


RN 150617-01-9 CAPLUS

CN 4H-Pyrazolo[4,3-c]quinolin-4-one, 3-amino-2,5-dihydro-5-(phenylmethyl)-  
(9CI) (CA INDEX NAME)




RN 150617-02-0 CAPLUS

CN 4H-Pyrazolo[4,3-c]quinolin-4-one, 3-amino-2,5-dihydro-5-(4-methoxyphenyl)-  
(9CI) (CA INDEX NAME)




RN 150617-03-1 CAPLUS


CN 4H-Pyrazolo[4,3-c]quinolin-4-one, 3-amino-5-(4-fluorophenyl)-2,5-dihydro-  
(9CI) (CA INDEX NAME)




RN 150617-04-2 CAPLUS  
 CN 4H-Pyrazolo[4,3-c]quinolin-4-one, 3-amino-2,5-dihydro-5-phenyl- (9CI) (CA INDEX NAME)



L30 ANSWER 29 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 1992:426302 CAPLUS <<LOGINID::20060919>>  
 DOCUMENT NUMBER: 117:26302  
 TITLE: Nucleophilic substitution and ring closure reactions of 4-chloro-3-nitro-2-quinolones  
 AUTHOR(S): Roschger, Peter; Fiala, Werner; Stadlbauer, Wolfgang  
 CORPORATE SOURCE: Inst. Org. Chem., Karl Franzens Univ. Graz, Graz, A-8010, Austria  
 SOURCE: Journal of Heterocyclic Chemistry (1992), 29(1), 225-31  
 CODEN: JHTCAD; ISSN: 0022-152X  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 GI



I



II

AB 4-Chloro-3-nitro-2-quinolones I [R1 = Me, Ph, R2 = H, R3 = Cl, R4 = NO2; R1R2 = (CH2)3, R3 = Cl, R4 = NO2], obtained from the corresponding


4-hydroxyquinolones by nitration and chlorination, reacted with sodium azide to give I (R3 = N3) which cyclized on thermolysis to yield the furoxanes II. Nucleophilic substitution reactions of I (R1 = Me, Ph, R2 = H, R3 = Cl, R4 = NO2) with NHR5R6 [R5 = H, R6 = H, Me, PhCH2, Ph; R5R6 = (CH2)5, (CH2)2O(CH2)2], KF, or R7OH (R7 = Me, Et, Ph) led to I [R3 = NR5R6, F, OMe, OEt, OPh], resp. With thiols either I (R1 = Me, Ph, R2 = H, R3 = SR8, R4 = NO2, R8 = Et, Me) or I (R3 = R4 = SR8) were obtained depending on the basic catalyst.

IT 141945-43-9P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 141945-43-9 CAPLUS

CN [1,2,5]Oxadiazolo[3,4-c]quinolin-4(5H)-one, 5-phenyl-, 3-oxide (9CI) (CA INDEX NAME)



L30 ANSWER 30 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1992:83503 CAPLUS <<LOGINID::20060919>>

DOCUMENT NUMBER: 116:83503

TITLE: Behavior of a naphthopyranone derivative towards some nitrogen and carbon nucleophiles

AUTHOR(S): Essawy, S. A.; El-Kady, M. Y.; Metwally, R. N.; El-Shenawy, A. I.

CORPORATE SOURCE: Fac. Sci., Benha Univ., Benha, Egypt



SOURCE: Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (1992), 31B(1), 39-43

CODEN: IJSBDB; ISSN: 0376-4699

DOCUMENT TYPE: Journal

LANGUAGE: English

GI





II

AB Oxobenzonaphthopyrandicarboxylic acid I has been prepared by cycloaddn. of naphthopyranone II with maleic anhydride. The reactions of I with amines, phosphorus pentachloride, Grignard reagents and aromatic hydrocarbons have been investigated.

IT 138793-98-3P 138793-99-4P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)


RN 138793-98-3 CAPLUS

CN Benzo[c]phenanthridine-7,8-dicarboxylic acid, 5,6,6a,7,8,9-hexahydro-9-(4-methoxyphenyl)-5-(4-methylphenyl)-6-oxo- (9CI) (CA INDEX NAME)



RN 138793-99-4 CAPLUS

CN Benzo[c]phenanthridine-7,8-dicarboxylic acid, 5,6,6a,7,8,9-hexahydro-9-(4-methoxyphenyl)-6-oxo-5-(phenylmethyl)- (9CI) (CA INDEX NAME)



L30 ANSWER 31 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1989:449360 CAPLUS <<LOGINID::20060919>>

DOCUMENT NUMBER: 111:49360

TITLE: Coordination chemical studies on copper(II) complexes of some derivatives of 4-hydroxy-2(1H)-quinolones

AUTHOR(S): Hassanein, M.; Abu-el-Wafa, S. M.

CORPORATE SOURCE: Dep. Inorg. Chem., Natl. Res. Cent., Cairo, Egypt


SOURCE: Zeitschrift fuer Anorganische und Allgemeine Chemie (1989), 570, 145-51

CODEN: ZAACAB; ISSN: 0044-2313

DOCUMENT TYPE: Journal

LANGUAGE: English

GI



AB CuL.4H2O (H2L = I, R = COCH2COMe, R1 = Ph, Me) and [CuL1.2H2O]ClO4 (HL1 = I, R = COMe, R1 = Ph, Me, Et, R = C(Me):NNH2, R1 = Me) were prepared and characterized by elemental anal., conductance, IR spectra and formation consts. Measurements of ligand field and ESR spectra as well as magnetic moments were also carried out. Generally, the obtained spectral results (electronic absorption energies and g values) showed that CuII ions are present in an axial elongated symmetry D4h (tetragonally distorted octahedron or square planar) depending on R. Moreover, the relatively low magnetic moment values (<1.74  $\mu_B$ ) measured at room temperature and some calculated G values (<4.0) suggested the presence of an appreciable metal-metal interaction.

IT 121566-55-0P 121596-20-1P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation and formation constant and crystal field splitting and ESR of)

RN 121566-55-0 CAPLUS


CN Copper(1+), (3-acetyl-1-phenyl-2,4(1H,3H)-quinolinedionato-03,04)diaqua-, (SP-4-3)-, perchlorate (9CI) (CA INDEX NAME)

CM 1

CRN 121566-54-9

CMF C17 H16 Cu N O5


CCI CCS



CM 2


CRN 14797-73-0

CMF C1 O4



RN 121596-20-1 CAPLUS

CN Copper, tetraaqua[3-(3-hydroxy-1-oxo-2-butenyl)-1-phenyl-2,4(1H,3H)-quinolinedionato(2-)]-, (OC-6-33)- (9CI) (CA INDEX NAME)



L30 ANSWER 32 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1988:204453 CAPLUS <<LOGINID::20060919>>

DOCUMENT NUMBER: 108:204453

TITLE: Some reactions with 3-aminocoumarin

AUTHOR(S): Hassan, H. M.; Bayomi, S. M.; Yousif, M. M.; Ali, M. M.

CORPORATE SOURCE: Fac. Sci., Mansoura Univ., Mansoura, Egypt


SOURCE: Pakistan Journal of Scientific and Industrial Research (1987), 30(8), 573-6

CODEN: PSIRAA; ISSN: 0030-9885


DOCUMENT TYPE: Journal

LANGUAGE: English

GI



I



II


AB (Phenylhydrazono)dihydrocoumarins I (R1 = H, Me, NO2) and acetamidocoumarins II (R2 = NHPh, substituted anilino, piperidino, NHNHPh) were prepared from the title compound Also prepared was II (R2 = thiocyanato).

IT 114125-84-7P


RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)

RN 114125-84-7 CAPLUS


CN 1,2,4-Triazino[5,6-c]quinolin-5(3H)-one, 6-(4-chlorophenyl)-2,6-dihydro-2,3-diphenyl- (9CI) (CA INDEX NAME)



L30 ANSWER 33 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 1980:550098 CAPLUS <<LOGINID::20060919>>  
 DOCUMENT NUMBER: 93:150098  
 TITLE: Photocyclization of enamides. Part 14. Substituent effects in the photocyclization of N- $\alpha,\beta$ -unsaturated acylanilides  
 AUTHOR(S): Ninomiya, Ichiya; Kiguchi, Toshiko; Yamauchi, Sadami; Naito, Takeaki  
 CORPORATE SOURCE: Kobe Women's Coll. Pharm., Kobe, 685, Japan  
 SOURCE: Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999) (1980), (1), 197-202  
 CODEN: JCPRB4; ISSN: 0300-922X  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 GI




AB Irradiation of  $\text{PhN}(\text{CH}_2\text{Ph})\text{COCR:CHR1}$  [e.g.,  $\text{RR1} = (\text{CH}_2)_4$ ;  $\text{R} = \text{Me}$ ,  $\text{R1} = \text{H}$ ] gave a mixture of cis and trans anthridones, e.g. I, or dihydroquinolones, e.g. II. Related acylanilides having an o- $\text{CO}_2\text{Me}$ ,  $\text{COMe}$ ,  $-\text{CN}$ , or  $-\text{CONH}_2$  substituent underwent [1,5] migration of the group to give trans lactams or dihydroquinolones, whereas anilides having an o- $\text{CO}_2\text{H}$  group gave decarboxy lactams.  
 IT 74480-89-0  
 RL: RCT (Reactant); RACT (Reactant or reagent) (reduction of)  
 RN 74480-89-0 CAPLUS  
 CN 6a(6H)-Phenanthridinecarboxylic acid, 5,7,8,9-tetrahydro-6-oxo-5-(phenylmethyl)-, methyl ester (9CI) (CA INDEX NAME)



L30 ANSWER 34 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 1979:458683 CAPLUS <<LOGINID::20060919>>  
 DOCUMENT NUMBER: 91:58683  
 TITLE: Azomethine metal complex pigments  
 INVENTOR(S): Chamberlain, Terence Richard; Campbell, Colin Dennis;  
 McCrae, James McGeachie  
 PATENT ASSIGNEE(S): Ciba-Geigy A.-G., Switz.  
 SOURCE: Brit., 12 pp.  
 CODEN: BRXXAA  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 1534787	A	19781206	GB 1976-27355	19760630
DE 2728864	A1	19780105	DE 1977-2728864	19770627
CA 1080231	A1	19800624	CA 1977-281560	19770628
FR 2356700	A1	19780127	FR 1977-19936	19770629
FR 2356700	B1	19800215		
JP 53003428	A2	19780113	JP 1977-78468	19770630
PRIORITY APPLN. INFO.: GI			GB 1976-27355	A 19760630



AB The preparation is described of pigments I (M = divalent transition metal, X = C2-8 alkylene residue, or isocyclic, aromatic, or heterocyclic residue; R = C1-6 alkyl, C6-10 aryl, C7-10 aralkyl; R1, R2 = H, halo, non-H2O-solubilizing group or (R1R2) = aromatic or heterocyclic residue). I are useful as lightfast pigments in a wide variety of organic media (e.g., surface coatings, inks, polymers, paints, plastics). Thus, a red shade yellow pigment [66005-94-5] was prepared from 3-formyl-4-hydroxy-1-methyl-2-quinolone [65740-49-0] by refluxing in EtOH with 3,4-(H2N)2C6H3NO2 [99-56-9] (4 h, yield 96.8%) followed by refluxing with Ni(OAc)2 in Me Cellosolve (3 h, yield 89.3%).  
 IT 66005-88-7 66009-94-7 66009-95-8


RL: USES (Uses)

(pigment, for coatings, preparation of)

RN 66005-88-7 CAPLUS

CN Nickel, [[3,3'-[1,2-phenylenebis(nitrilomethylidyne)]bis[1-phenyl-2,4(1H,3H)-quinolinedionato]](2-)-N3,N3',O4,O4']- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 66009-94-7 CAPLUS

CN Nickel, [[2,2'-[1,2-phenylenebis(nitrilomethylidyne)]bis[4-phenylbenzo[f]quinoline-1,3(2H,4H)-dionato]](2-)-N2,N2',O1,O1']- (9CI) (CA INDEX NAME)



RN 66009-95-8 CAPLUS  
 CN Nickel, [[3,3'-[1,2-phenylenebis(nitrilomethylidyne)]bis[1-phenylbenzo[h]quinoline-2,4(1H,3H)-dionato]](2-)-N3,N3',O4,O4']- (9CI)  
 (CA INDEX NAME)



L30 ANSWER 35 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 1978:154316 CAPLUS <<LOGINID::20060919>>  
 DOCUMENT NUMBER: 88:154316  
 TITLE: Metal complex pigments  
 INVENTOR(S): Chamberlain, Terence Richard; Campbell, Colin Dennis;  
 McCrae, James McGeachie  
 PATENT ASSIGNEE(S): Ciba-Geigy A.-G., Switz.  
 SOURCE: Ger. Offen., 26 pp.  
 CODEN: GWXXBX  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2728864	A1	19780105	DE 1977-2728864	19770627
GB 1534787	A	19781206	GB 1976-27355	19760630
			GB 1976-27355	A 19760630

PRIORITY APPLN. INFO.:

GI For diagram(s), see printed CA Issue.

AB Azomethine pigments I (R = C1-6 alkyl, C6-10 aryl, C7-10 aralkyl; R1, R2 = H, halogen, or non-water-solubilizing group, or R1R2 = aromatic or heterocyclic residue; M is a divalent transition metal; Z = atom to complete an aryl, isocyclic, or heterocyclic residue) are prepared for use as fast colorants for plastics and coatings. Thus, a mixture of 3-formyl-4-hydroxy-1-methyl-2-quinolone [65740-49-0] and 3,4-diaminonitrobenzene [99-56-9] was refluxed in EtOH to give the azomethine ligand [66011-55-0] which was treated with Ni(OAc)2.4H2O in methyl cellosolve to give I (R = Me, R1 = R2 = H, X = atoms to complete 1,2-diamino-4-nitrobenzene, M = Ni) [66005-94-5], a reddish yellow pigment. The other I were similarly prepared


IT 66005-88-7 66009-94-7 66009-95-8

RL: USES (Uses)


(pigment, for coatings, preparation of)

RN 66005-88-7 CAPLUS


CN Nickel, [[3,3'-[1,2-phenylenebis(nitrilomethylidyne)]bis[1-phenyl-2,4(1H,3H)-quinolinedionato]](2-)-N3,N3',O4,O4']- (9CI) (CA INDEX NAME)



RN 66009-94-7 CAPLUS  
 CN Nickel, [[2,2'-[1,2-phenylenebis(nitrilomethylidyne)]bis[4-phenylbenzo[f]quinoline-1,3(2H,4H)-dionato]](2-)-N2,N2',O1,O1']- (9CI)  
 (CA INDEX NAME)



RN 66009-95-8 CAPLUS  
 CN Nickel, [[3,3'-[1,2-phenylenebis(nitrilomethylidyne)]bis[1-phenylbenzo[h]quinoline-2,4(1H,3H)-dionato]](2-)-N3,N3',O4,O4']- (9CI)  
 (CA INDEX NAME)



L30 ANSWER 36 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 1978:122660 CAPLUS <<LOGINID::20060919>>  
 DOCUMENT NUMBER: 88:122660  
 TITLE: Heterocyclic azomethine-metal complex dyes  
 INVENTOR(S): Chamberlain, Terence Richard; Campbell, Colin Dennis;  
 McCrae, James McGeachie  
 PATENT ASSIGNEE(S): Ciba-Geigy A.-G., Switz.  
 SOURCE: Ger. Offen., 29 pp.  
 CODEN: GWXXBX  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2728863	A1	19780105	DE 1977-2728863	19770627
GB 1532098	A	19781115	GB 1976-27356	19760630
US 4153601	A	19790508	US 1977-810247	19770627
CA 1092121	A1	19801223	CA 1977-281603	19770628
DK 7702893	A	19771231	DK 1977-2893	19770629
FR 2356699	A1	19780127	FR 1977-19935	19770629
FR 2356699	B1	19781103		
JP 53013633	A2	19780207	JP 1977-78469	19770630
BR 7704300	A	19780404	BR 1977-4300	19770630
			GB 1976-27356	A 19760630

PRIORITY APPLN. INFO.:

GI For diagram(s), see printed CA Issue.


AB Azomethine pigments (I; R = H, C1-6 alkyl, C6-10 aryl, C7-10 aralkyl; R1 = H, Me; R2 and R3 = non-water-solubilizing group or R2R3 = condensed aromatic ring; R4,R5 = H, C1-22 alkyl; R6 = H, C1-22 alkyl, C6-10 aryl (R4, R5, R6 alkyl groups may be substituted or be interrupted by O, S, or N bridges); R4R5R6N may be a heterocyclic residue; A = an optionally substituted aryl, isocyclic, heterocyclic ring; n = 0, 1) are prepared and used in coatings, giving fast yellow to red shades. Thus, a mixture of 3-formyl-4-hydroxy-1-methyl-2-quinolone [65740-49-0] and 2-aminophenol [95-55-6] in EtOH were refluxed, the product [65740-71-8] isolated in 91% yield, and treated with copper acetate in Me cellosolve to give yellowish green I(R = Me, R1 = R2 = R3 = H, n = 0, A = benzene residue) [65803-19-2]. Other I were similarly prepared

IT 65750-72-3P 65750-73-4P 65750-75-6P  
 65815-00-1P


RL: IMF (Industrial manufacture); PREP (Preparation)  
 (preparation of)

RN 65750-72-3 CAPLUS


CN Copper, [2-[[[(2-hydroxyphenyl)imino]methyl]-4-phenylbenzo[f]quinoline-1,3(2H,4H)-dionato(2-)-N2,O1,O2]- (9CI) (CA INDEX NAME)



RN 65750-73-4 CAPLUS  
 CN Copper, [3-[[[(2-hydroxyphenyl)imino]methyl]-1-phenyl-2,4(1H,3H)-quinolinedionato(2-)-N3,O3,O4]- (9CI) (CA INDEX NAME)



RN 65750-75-6 CAPLUS  
 CN Copper, [3-[[[(2-hydroxyphenyl)imino]ethyl]-1-phenyl-2,4(1H,3H)-quinolinedionato(2-)-N3,O3,O4]- (9CI) (CA INDEX NAME)



RN 65815-00-1 CAPLUS  
 CN Copper, [3-[[[(2-hydroxyphenyl)imino]methyl]-1-phenylbenzo[h]quinoline-2,4(1H,3H)-dionato(2-)]- (9CI) (CA INDEX NAME)

